{"gene":"POU3F2","run_date":"2026-06-10T06:43:35","timeline":{"discoveries":[{"year":1995,"finding":"Deletion of the Brn-2 genomic locus in mice results in failure of differentiation of paraventricular and supraoptic nucleus neurons, inability to activate neuropeptide-encoding genes (including vasopressin and oxytocin), and failure of correct axonal projections, demonstrating that Brn-2 is required at a penultimate step in hypothalamic neurosecretory neuron differentiation.","method":"Gene knockout (homologous recombination in ES cells), histology, gene expression analysis","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — two independent knockout studies (PMID:8543156 and PMID:8543155) using gene targeting with concordant phenotypes in multiple labs","pmids":["8543156","8543155"],"is_preprint":false},{"year":1993,"finding":"Antisense RNA-mediated inhibition of Brn-2 induction in P19 embryonal carcinoma cells blocks differentiation into neurons and astrocytes, causing cells to instead differentiate into non-neural cell types (smooth and skeletal muscle), demonstrating that Brn-2 is required for establishing neural cell lineages.","method":"Antisense RNA inhibition in P19 cells, morphological and lineage marker analysis","journal":"Neuron","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with defined cellular phenotype and lineage markers, single lab","pmids":["8274283"],"is_preprint":false},{"year":2003,"finding":"Brn-2 is expressed in Schwann cells with a developmental profile similar to Oct-6; overexpression of Brn-2 under the Oct-6 Schwann cell enhancer partially rescues the developmental delay in Oct-6-deficient Schwann cells; compound disruption of both Brn-2 and Oct-6 produces a much more severe myelination phenotype, demonstrating that Brn-2 function largely overlaps with Oct-6 in driving the promyelinating-to-myelinating transition.","method":"Transgenic overexpression rescue in Oct-6 knockout, compound knockout, developmental expression profiling","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with rescue and compound knockout, multiple orthogonal approaches in single study","pmids":["12782656"],"is_preprint":false},{"year":2006,"finding":"Oct6 and Brn2 directly activate Krox20 expression in Schwann cells by binding to a defined Krox20 enhancer element during the promyelin-to-myelin transition; Sox10 synergizes with these POU proteins on this enhancer, placing Brn2 directly upstream of Krox20 in the myelination transcriptional hierarchy.","method":"Cell culture reporter assays, transgenic enhancer analysis, transcription factor binding studies","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct enhancer binding and reporter assays combined with transgenesis, multiple orthogonal methods in single study","pmids":["16311519"],"is_preprint":false},{"year":2004,"finding":"Brn-2 expression in melanoma is strongly upregulated downstream of Ras and MAPK signaling; the Brn-2 promoter is stimulated by kinase-activating BRAF mutants; siRNA-mediated depletion of BRAF reduces endogenous Brn-2 expression; and siRNA depletion of Brn-2 in BRAF-activated melanoma cells decreases proliferation, placing Brn-2 as a downstream effector of BRAF signaling in melanoma proliferation.","method":"Promoter reporter assays, siRNA knockdown, proliferation assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (promoter assays, BRAF knockdown epistasis, Brn-2 knockdown phenotype), replicated across two concurrent publications","pmids":["15024080"],"is_preprint":false},{"year":2004,"finding":"Brn-2 expression is directly controlled by the Wnt/beta-catenin signaling pathway in melanoma cell lines and transgenic mice; siRNA inhibition of Brn-2 in beta-catenin-overexpressing melanoma cells results in decreased proliferation, identifying Brn-2 as a convergence point for BRAF and Wnt/beta-catenin signaling in melanoma proliferation.","method":"Promoter reporter assays, siRNA knockdown, transgenic mice, proliferation assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct promoter regulation demonstrated with reporter assays and transgenic validation, functional knockdown phenotype, same lab as PMID:15024080","pmids":["15024079"],"is_preprint":false},{"year":2008,"finding":"Brn-2 directly represses Mitf expression in melanoma cells, and Brn-2 and Mitf mark distinct non-overlapping subpopulations within melanoma biopsies, demonstrating Brn-2 as a regulator of tumor heterogeneity through direct MITF repression.","method":"Promoter reporter assays, siRNA knockdown, immunohistochemistry of biopsies","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct promoter repression shown with reporter assays, siRNA knockdown, validated in clinical samples","pmids":["18829533"],"is_preprint":false},{"year":1999,"finding":"PQBP-1, a novel polyglutamine tract-binding protein, binds directly to the polyglutamine tract of Brn-2 and inhibits Brn-2-mediated transcriptional activation in cells.","method":"Protein identification by binding, co-transfection transcriptional assays, nuclear localization studies","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct protein interaction with functional transcriptional inhibition shown, single lab with multiple methods","pmids":["10332029"],"is_preprint":false},{"year":2000,"finding":"Brn-2 homodimerizes in vivo; dimerization requires both the homeodomain and linker regions of the POU domain. Brn-2 also shows low-affinity interactions with TBP, the transcriptional coactivator p300, and with the melanocyte transcription factors Sox-10 and Pax-3.","method":"GAL4-VP16 two-hybrid assay, GST-pulldown, EMSA with melanoma nuclear extracts","journal":"European journal of biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple in vitro binding methods (two-hybrid, GST-pulldown, EMSA) in single study, single lab","pmids":["11029584"],"is_preprint":false},{"year":2012,"finding":"Brn-2 directly represses CDH13 (T-cadherin) promoter activity in melanoma cells; BRN2 binds to a specific element at -219 bp of the CDH13 promoter (5'-CATGCAAAA-3'); ectopic BRN2 suppresses CDH13 promoter activity, and BRN2 knockdown restores T-cadherin expression.","method":"Reporter gene assays, EMSA, siRNA knockdown, ectopic expression","journal":"Laboratory investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct promoter binding and repression demonstrated with EMSA and reporter assays plus functional validation, single lab","pmids":["23069940"],"is_preprint":false},{"year":2012,"finding":"PI3K signaling positively regulates Brn-2 expression in melanoma via Pax3; Pax3 directly binds and activates the Brn-2 promoter; PI3K inhibition reduces both Pax3 and Brn-2 expression and decreases melanoma invasiveness, placing Brn-2 downstream of a PI3K-Pax3 axis.","method":"PI3K inhibitor treatment, promoter binding assays, siRNA knockdown, invasion assays","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct promoter binding demonstrated, epistasis established via inhibitor and knockdown, single lab","pmids":["22988297"],"is_preprint":false},{"year":2012,"finding":"Phosphorylation of BRN2 at T361 and S362 within the POU domain differentially regulates its transcriptional targets: phosphorylated BRN2 (BRN2TS) induces proliferation and represses migration and activates PAX3 transcription, while non-phosphorylatable BRN2 (BRN2AA) represses both proliferation and migration, and represses PAX3. Both forms repress MITF-M.","method":"Point mutagenesis, transgenic mouse models, in vitro cell assays, gene expression analysis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — active-site mutagenesis validated in both in vitro and transgenic in vivo settings, multiple phenotypic readouts, single lab","pmids":["22290434"],"is_preprint":false},{"year":2010,"finding":"POU3F2/BRN2 occupies approximately 2108 genomic loci in melanoma cells including the MITF promoter and the Kit ligand (Kitl) proximal promoter; BRN2 regulates Kitl expression via a cluster of four closely spaced binding sites, indicating BRN2 can drive autocrine KIT ligand signaling.","method":"ChIP-chip genome-wide occupancy profiling, luciferase reporter assays","journal":"Pigment cell & melanoma research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genome-wide ChIP-chip combined with functional reporter validation for Kitl, single lab","pmids":["20337985"],"is_preprint":false},{"year":2016,"finding":"Androgen receptor (AR) directly suppresses BRN2 transcription in prostate cancer; loss of AR activity leads to elevated BRN2 expression; BRN2 is required for neuroendocrine prostate cancer (NEPC) and regulates the NEPC marker SOX2, placing BRN2 downstream of AR suppression as a driver of neuroendocrine differentiation.","method":"AR pathway inhibition models, ChIP assays demonstrating direct AR binding to BRN2 promoter, siRNA knockdown, in vitro and xenograft functional assays","journal":"Cancer discovery","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct AR binding to BRN2 promoter by ChIP, multiple functional assays in vitro and in vivo, validated in clinical samples","pmids":["27784708"],"is_preprint":false},{"year":2019,"finding":"BRN2 associates with DNA damage response proteins PARP1 and Ku70/Ku80 (not transcriptional cofactors); BRN2 is rapidly recruited to DNA damage sites in a PARP1-dependent manner; BRN2 facilitates Ku80 recruitment and promotes non-homologous end joining (NHEJ) at the expense of homologous recombination; BRN2 also suppresses an apoptosis-associated gene expression program, protecting against UVB-, chemotherapy-, and vemurafenib-induced apoptosis.","method":"Co-immunoprecipitation, live-cell imaging of DNA damage recruitment, NHEJ/HR repair assays, gene expression analysis, apoptosis assays","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP with PARP1/Ku proteins, PARP1-dependency demonstrated, multiple functional DNA repair and apoptosis assays, mechanistically distinct from transcriptional role","pmids":["30804224"],"is_preprint":false},{"year":2018,"finding":"Loss of CDKN2A leads to increased BRN2 expression via E2F1; E2F1 directly regulates BRN2 transcription; BRN2 inhibition rescues metastatic dissemination caused by CDKN2A loss in human melanoma lines in mice, placing BRN2 downstream of CDKN2A/p16-E2F1 in melanoma invasion initiation.","method":"CRISPR-Cas9 engineering of primary human melanocytes, xenograft models, E2F1 promoter binding assays","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — CRISPR-engineered primary human cells, in vivo rescue experiment, direct E2F1 regulation demonstrated, multiple orthogonal methods","pmids":["29990501"],"is_preprint":false},{"year":2011,"finding":"BRN2 activates NOTCH pathway signaling in melanoma cells, while MITF represses it; siRNA-mediated depletion of BRN2 decreased NOTCH pathway member expression, and depletion of MITF increased it; loss of both BRN2 and MITF decreased melanosphere-forming capability, cell adhesion, and invasion.","method":"siRNA knockdown, gene expression analysis, melanosphere formation assay, invasion assay","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA-based loss-of-function with multiple phenotypic readouts and pathway analysis, single lab","pmids":["21358674"],"is_preprint":false},{"year":2013,"finding":"BRN2 is required for expression of ASCL1, ND1, and neuroendocrine markers (NCAM1, SYP, CHGA) in small cell lung cancer cells; BRN2 knockdown in SCLC cells causes significant growth retardation with decreased S-to-G2 phase population; forced BRN2 expression in non-SCLC cells induces expression of these neuroendocrine markers, placing BRN2 as a higher-level regulator than ASCL1 and ND1.","method":"siRNA knockdown, ectopic expression, cell cycle analysis, growth assays","journal":"Pathology international","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — bidirectional (knockdown and overexpression) functional experiments with defined phenotypic readouts, single lab","pmids":["23530560"],"is_preprint":false},{"year":2013,"finding":"BRN2 directly activates TTF1 expression in SCLC cells by binding to the TTF1 isoform 2 promoter; BRN2 binding to the TTF1 promoter was confirmed by chromatin immunoprecipitation; BRN2 knockdown significantly reduced TTF1 expression.","method":"Promoter reporter assays, ChIP, siRNA knockdown","journal":"Laboratory investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct promoter binding confirmed by ChIP plus functional knockdown, single lab","pmids":["23358112"],"is_preprint":false},{"year":2005,"finding":"Brn-2 directly interacts with Jab1 (Jun-activation-domain-binding protein 1); interaction was identified by yeast two-hybrid and confirmed by surface plasmon resonance biosensor.","method":"Yeast two-hybrid screen, surface plasmon resonance biosensor","journal":"Neuroscience letters","confidence":"Low","confidence_rationale":"Tier 3 / Weak — protein interaction confirmed by two methods but functional consequence not established, single lab","pmids":["15911144"],"is_preprint":false},{"year":2001,"finding":"Brn-2 activates the neuronal promoter of the aromatic L-amino acid decarboxylase (AADC) gene; NF-Y binding is required for Brn-2-mediated transactivation; Brn-2 directly interacts with NF-Y via its POU domain (GST-pulldown), and NF-Y and Brn-2 bind cooperatively to the AADC neuronal promoter.","method":"Reporter gene assays, dominant-negative NF-Y, GST-pulldown, EMSA","journal":"Brain research. Molecular brain research","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro binding reconstitution (GST-pulldown and EMSA) combined with functional reporter assays, single lab","pmids":["11311976"],"is_preprint":false},{"year":2004,"finding":"Brn-2 POU domain dimerizes cooperatively on a palindromic MORE+2-type element (TB motif) in the AADC neuronal promoter; site-directed mutagenesis of the POU-specific domain hydrophobic pocket and C-terminal POU homeodomain abolished dimerization on TB; both TB and ONF sites contribute to Brn-2-mediated promoter activation.","method":"EMSA with POU domain mutants, site-directed mutagenesis, reporter assays in COS-7 cells","journal":"Brain research. Molecular brain research","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — mutagenesis defining dimerization interface combined with functional reporter assays, single lab","pmids":["14741405"],"is_preprint":false},{"year":2017,"finding":"BRN2 drives melanoma cell migration and invasion through induction of NFIB; NFIB in turn upregulates EZH2, which epigenetically suppresses MITF expression; this BRN2-NFIB-EZH2-MITF axis promotes an invasive, less proliferative melanoma phenotype.","method":"Overexpression and siRNA knockdown experiments, migration/invasion assays, gene expression analysis","journal":"EBioMedicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis established through sequential knockdown/overexpression with defined phenotypic readouts, single lab","pmids":["28119061"],"is_preprint":false},{"year":2012,"finding":"POU-III transcription factors Pou3f2 (Brn2) and Pou3f3 (Brn1) are expressed in ventricular zone progenitors and function to promote upper-layer cortical neuron fate; using an Engrailed dominant-negative repressor, sustained neurogenesis after the deep-to-upper-layer transition requires Pou3f activity; single-gene overexpression of any Pou3f in early neural progenitors is sufficient to specify precocious Satb2+ upper-layer neuron birth. Pou3fs suppress Notch effector Hes5 and promote Tbr2 and Tbr1 expression.","method":"Dominant-negative repressor, single-gene overexpression, marker analysis, in utero electroporation","journal":"Cerebral cortex","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — dominant-negative and overexpression with defined lineage markers, pathway placement via Notch/Tbr2, single lab","pmids":["22892427"],"is_preprint":false},{"year":2015,"finding":"Brn2 is essential for the neuronal differentiation program in retinoic acid-treated embryonic stem cells; integrated RNA-seq (after Brn2 silencing) and ChIP-seq identified Zic1 as a direct Brn2 target gene; shRNA silencing of Zic1 blocked neural precursor specification, defining a hierarchical Brn2-Zic1 axis specifying neuronal fate.","method":"shRNA knockdown, RNA-seq, ChIP-seq, differentiation assays","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide ChIP-seq integrated with RNA-seq, epistasis confirmed via downstream target knockdown, multiple orthogonal methods","pmids":["25991548"],"is_preprint":false},{"year":2016,"finding":"A prenatal β-catenin/Brn2/Tbr2 transcriptional cascade governs basal neural progenitor cell expansion; in Dvl1/Dvl3 mutant mice with social and repetitive behavioral abnormalities, this cascade is deregulated; pharmacological Wnt activation rescues the transcriptional cascade and prevents adult behavioral deficits.","method":"Genetic mouse model (Dvl mutants), pharmacological Wnt activation, transcriptional cascade analysis","journal":"Molecular psychiatry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cascade validated by rescue experiment in defined genetic model, single lab","pmids":["26830142"],"is_preprint":false},{"year":2016,"finding":"POU3F2 lies downstream of SIM1 and controls oxytocin expression in the hypothalamic neuroendocrine preoptic area, as demonstrated using morpholino and mutant zebrafish models.","method":"Morpholino knockdown and mutant zebrafish models, oxytocin expression analysis","journal":"American journal of human genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with defined molecular phenotype (oxytocin expression) in two model systems, epistasis to SIM1 established","pmids":["26833329"],"is_preprint":false},{"year":2018,"finding":"POU3F2 directly regulates NTF3 promoter activity; POU3F2 binds to the NTF3 promoter as demonstrated by ChIP-seq and mutation/deletion of the POU3F2 binding site in the NTF3 promoter decreased luciferase reporter activity; POU3F2 knockdown downregulates NTF3 expression; exogenous NTF3 rescues neuronal differentiation in POU3F2-knockdown cells.","method":"ChIP-seq, promoter luciferase reporter assays with binding site mutation, siRNA knockdown, rescue experiments","journal":"Molecular neurobiology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct binding confirmed by ChIP-seq plus mutagenesis of binding site and functional rescue, single lab with multiple orthogonal methods","pmids":["29549646"],"is_preprint":false},{"year":2018,"finding":"POU3F2 regulates TRIM8 expression by binding to a SNP-containing promoter element (rs5011218); luciferase reporter and EMSA showed that POU3F2 binds this element and that the SCZ-associated SNP affects binding efficiency; POU3F2 or TRIM8 knockdown in neural progenitor cells promotes NPC proliferation, inhibits neuronal differentiation, and impairs excitatory synaptic transmission.","method":"Luciferase reporter assays, EMSA, RNA-seq after knockdown, functional NPC assays, electrophysiology","journal":"Molecular psychiatry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct promoter binding with EMSA plus functional cellular assays, single lab, multiple methods","pmids":["32929213"],"is_preprint":false},{"year":2021,"finding":"Brn2 associates with condensed chromatin throughout cell division in neural stem cells (live-cell imaging); ChIP-seq shows Brn2 mitotic chromosome binding is not sequence-specific (relies mostly on electrostatic forces); competing with Brn2 binding during mitotic exit using a mitotic-specific dominant-negative reduces transcription of its target gene Nestin, demonstrating Brn2's role in early transcriptional reactivation during mitosis-to-G1 transition.","method":"Live-cell imaging, ChIP-seq, single-molecule RNA-FISH, mitotic dominant-negative approach","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — live-cell imaging combined with genome-wide ChIP-seq, smRNA-FISH, and functional dominant-negative, multiple orthogonal methods in single study","pmids":["34168041"],"is_preprint":false},{"year":2010,"finding":"Mutant huntingtin N-terminal fragment (from R6/2 HD mice) sequesters Brn-2, reducing its DNA binding; mutant huntingtin also reduces Brn-2 transcription; both mechanisms reduce Brn-2 function, leading to reduced hypothalamic neuropeptide expression. Brn-1, a related protein, is not sequestered.","method":"Comprehensive analysis of transcription factor DNA binding, protein interaction studies, R6/2 model mice","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — DNA binding and protein interaction assays in vivo in disease model, with negative control (Brn-1 not sequestered), single lab","pmids":["20185558"],"is_preprint":false},{"year":2020,"finding":"BRN2 directly binds PARP1 and Ku70/Ku80 and is rapidly recruited to DNA damage sites in a PARP1-dependent manner; BRN2 facilitates Ku80 recruitment and promotes non-homologous end-joining (NHEJ) at the expense of homologous recombination; this is associated with high somatic mutation burden in melanoma.","method":"Co-immunoprecipitation, live-cell imaging, NHEJ/HR repair pathway assays","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, PARP1-dependency experiment, multiple repair pathway assays, mechanistically novel finding with multiple methods","pmids":["30804224"],"is_preprint":false},{"year":2020,"finding":"BRN2 expression increases anoikis resistance in melanoma cells; induction of BRN2 increases c-MET protein levels and STAT3 phosphorylation; treatment with c-MET inhibitors decreases viability of BRN2-expressing cells under non-adherent conditions.","method":"Doxycycline-inducible BRN2 expression, genome-wide profiling, non-adherent viability assays, c-MET inhibitor treatment","journal":"Oncogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — inducible expression system with genome-wide profiling and pharmacological validation, single lab","pmids":["32632141"],"is_preprint":false},{"year":2021,"finding":"BRN2 directly induces PTEN expression and represses PI3K signaling; BRN2 haplo-insufficiency in a BrafV600E/PtenF/+ context promotes melanoma initiation and metastasis; MITF (a BRN2 target) represses PTEN transcription, suggesting a tumor suppressive role for BRN2 via PTEN induction.","method":"Conditional knockout mouse models, promoter binding assays, PI3K signaling analysis","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo conditional knockout model with mechanistic promoter analysis, single lab","pmids":["34140478"],"is_preprint":false},{"year":2018,"finding":"BRAF regulates MITF expression through a BRN2/PAX3 rheostat: PAX3 activates MITF transcription while BRN2 represses it; the balance between BRN2 and PAX3 determines MITF expression plasticity, providing robustness during MAPK inhibitor treatment.","method":"Reporter assays, knockdown/overexpression, quantification of transcription factor levels","journal":"Pigment cell & melanoma research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic reporter and epistasis assays identifying BRN2/PAX3 competition, single lab","pmids":["30277012"],"is_preprint":false},{"year":2020,"finding":"Cdk5 phosphorylates Tet3 at S1310 and S1379 in its catalytic domain; phosphorylated Tet3 generates higher 5hmC levels at the BRN2 promoter (compared to phospho-mutant Tet3), correlating with higher BRN2 expression and more efficient neuronal differentiation of ESCs; differential H2A.Z occupancy at BRN2 promoter also participates in this regulation.","method":"In vitro dioxygenase assay with phospho-mutant Tet3, 5hmC mapping at BRN2 promoter, ESC differentiation assays, Tet triple-KO rescue experiments","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — phospho-mutant analysis with promoter 5hmC measurement and functional differentiation readout, single lab with multiple methods","pmids":["31807777"],"is_preprint":false},{"year":2018,"finding":"POU3F2 regulates a coexpression network module in brain; knockdown and overexpression experiments in neural cells validate POU3F2 as a regulator of hsa-miR-320e and target mRNAs in this module; POU3F2 knockdown or overexpression in SH-SY5Y cells and human neural progenitor cells modulates gene expression in schizophrenia/bipolar-associated gene networks.","method":"siRNA knockdown and overexpression in neural cell lines and human neural progenitor cells, RNA-seq","journal":"Science translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — bidirectional expression manipulation in relevant cell types with transcriptomic validation, replicated in PsychENCODE datasets","pmids":["30545964"],"is_preprint":false},{"year":2024,"finding":"BRN2 in cynomolgus monkey biallelic knockout (lethal before midgestation) decreases radial glia cell expansion, induces precocious differentiation, and alters neurogenesis trajectory in the telencephalon; BRN2 directly regulates SOX2 and STAT3 and maintains HOPX expression; BRN2 controls specification and differentiation of ganglionic eminences, revealing primate-specific mechanistic functions.","method":"Biallelic knockout in cynomolgus monkeys (CRISPR), single-cell transcriptome, histology, target gene expression analysis","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo biallelic knockout in non-human primate combined with single-cell transcriptomics and target gene validation, novel mechanistic finding","pmids":["35245119"],"is_preprint":false},{"year":2024,"finding":"BRN1 and BRN2 have an evolutionarily conserved function in neocortical progenitors to control proliferative capacity and the switch from direct to indirect neurogenesis; BRN1/2 act in concert with NOTCH and primary microcephaly genes; this is validated in mice, ferrets, and transcriptomic data from genetically modified macaques.","method":"Conditional knockout in mice and ferrets, transcriptomics in genetically modified macaques, functional epistasis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — multi-species genetic and functional validation with cross-species replication and defined cellular phenotypes","pmids":["39271675"],"is_preprint":false},{"year":2025,"finding":"POU3F2 mutation in human neural progenitor cells reduces canonical Wnt signalling and decreases proliferation, causing premature radial glia specification; SOX13 and ADNP are direct transcriptional targets of POU3F2 that mediate its effects on Wnt signaling; loss-of-function mutations in POU3F2 are found in individuals with autism spectrum disorder.","method":"CRISPR-mediated POU3F2 disruption in human NPCs, RNA-seq, ChIP-seq, Wnt pathway reporter assays","journal":"Brain","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR loss-of-function in human NPCs with target gene validation via multiple omics approaches, single lab","pmids":["40498903"],"is_preprint":false},{"year":2023,"finding":"POU3F2 promotes radioresistance in triple-negative breast cancer by interacting with ARNT2 and enhancing Akt pathway activation; Co-IP demonstrated POU3F2-ARNT2 interaction; POU3F2 knockdown decreased radioresistance and reduced proliferation and invasion.","method":"Co-immunoprecipitation, siRNA knockdown, clonogenic survival assays, xenograft model","journal":"Breast cancer research and treatment","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — Co-IP plus functional knockdown with multiple assays including in vivo, single lab","pmids":["36797433"],"is_preprint":false},{"year":2024,"finding":"RFX4 directly interacts with the promoters of POU3F2 and NEUROD1, acting as an upstream regulator; ectopic expression of RFX4 drives human embryonic stem cells toward a neuronal fate; CRISPR-Cas9 knockout of RFX4 reduces POU3F2 expression and impairs neuronal differentiation.","method":"Multi-omics (ATAC-seq, ChIP-seq, Hi-C, RNA-seq), RFX4 knock-in and CRISPR-Cas9 knockout, neuronal differentiation assays","journal":"Cellular and molecular life sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct promoter binding confirmed by ChIP-seq and multi-omics, bidirectional functional validation, single lab","pmids":["38386071"],"is_preprint":false},{"year":2021,"finding":"Integrin α3β1 promotes BRN2 expression in triple-negative breast cancer cells via Akt signaling; RNAi suppression of α3β1 reduces Brn-2 mRNA, protein, and BRN2 promoter activity; Akt inhibitor reduces both Brn-2 expression and invasion; exogenous Brn-2 partially restores invasion in α3β1-suppressed cells.","method":"RNAi knockdown, promoter reporter assays, pharmacological Akt inhibition, invasion assays in vitro and in vivo","journal":"Cancers","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis through knockdown, pharmacological inhibition, and rescue experiments, multiple functional assays, single lab","pmids":["33513758"],"is_preprint":false},{"year":2017,"finding":"Deletion of the three homopolymeric amino acid repeats (polyG, polyQ, polyP) from the Pou3f2 transactivation domain (Pou3f2Δ/Δ mice) causes cognitive impairment and reduced adult hippocampal neurogenesis, with fewer newborn neurons in the dentate gyrus, demonstrating a functional role for these mammalian-specific repeats in cognitive function and neurogenesis.","method":"Knock-in mouse model, behavioral testing (object recognition/location), immunohistochemistry for doublecortin and BrdU/NeuN co-labeling","journal":"Genes, brain, and behavior","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — knock-in mouse model with defined domain deletion, multiple behavioral and cellular readouts, single lab","pmids":["28782255"],"is_preprint":false},{"year":2014,"finding":"Replacement of mammalian Pou3f2 with the Xenopus ortholog lacking homopolymeric amino acid repeats (nonmammalized mice) causes deficits in maternal pup retrieval behavior and decreases in dopamine and serotonin synthesis rate-limiting enzymes; knock-in mice lacking the mammalian-specific polyAA repeats show similar results, demonstrating that these mammalian-specific sequences are required for normal monoamine levels and maternal behavior.","method":"Knock-in mice with Xenopus ortholog replacement, knock-in mice with polyAA deletions, behavioral testing, immunohistochemical quantification of monoamine synthesis enzymes","journal":"Genome biology and evolution","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two complementary knock-in models with defined molecular and behavioral phenotypes, single lab","pmids":["24709564"],"is_preprint":false},{"year":1999,"finding":"Brn-2 is required as an intermediary for retinoic acid-induced CRF gene transcription in human neuroblastoma BE(2)-M17 cells; antisense Brn-2 aborts RA-mediated CRF induction, but Brn-2 overexpression alone is not sufficient for CRF expression without RA.","method":"Antisense RNA inhibition, ectopic overexpression, reporter gene assays","journal":"Molecular endocrinology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, antisense inhibition with limited mechanistic follow-up, negative overexpression result also reported","pmids":["10446900"],"is_preprint":false},{"year":2008,"finding":"BRN2 knockdown does not alter nestin expression in melanoma cells (negative result); SOX9 and SOX10, but not BRN2, are required for nestin expression in melanoma cells, as SOX9/SOX10 knockdown markedly decreased nestin levels.","method":"siRNA knockdown, Western blot and mRNA analysis","journal":"The Journal of investigative dermatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean siRNA knockdown with clear negative result for BRN2 and positive result for SOX9/SOX10, single lab","pmids":["18923447"],"is_preprint":false},{"year":2003,"finding":"Adenoviral overexpression of Brn-2 in the rat paraventricular nucleus had no effect on vasopressin hnRNA levels, and did not upregulate CRF mRNA in vivo, despite Brn-2 transactivating the proximal CRF promoter in vitro; this indicates Brn-2 is not rate-limiting for VP or CRF expression in adult hypothalamus.","method":"Adenoviral-mediated in vivo overexpression in rat PVN, hnRNA and mRNA analysis","journal":"Molecular and cellular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct in vivo overexpression experiment with clear negative result in adult tissue, single lab","pmids":["12644309"],"is_preprint":false}],"current_model":"POU3F2/BRN2 is a class III POU domain transcription factor that functions as a sequence-specific transcriptional activator and repressor (of MITF, CDH13, PTEN) and a direct regulator of neural lineage specification, hypothalamic neurosecretory neuron differentiation, Schwann cell myelination (via direct Krox20 enhancer activation), and cortical progenitor behavior; in melanoma it sits downstream of BRAF/MAPK, Wnt/β-catenin, PI3K-Pax3, and CDKN2A-E2F1 signaling to drive invasion and phenotype switching, and also associates non-transcriptionally with PARP1 and Ku70/Ku80 at DNA damage sites to promote error-prone NHEJ repair and suppress apoptosis."},"narrative":{"mechanistic_narrative":"POU3F2 (BRN2) is a class III POU-domain transcription factor that acts as a master regulator of neural lineage specification and neuronal differentiation, and is co-opted in cancer as a driver of phenotype switching and invasion [PMID:8274283, PMID:25991548, PMID:29990501]. In the nervous system it is required at a penultimate step of hypothalamic neurosecretory neuron differentiation, enabling activation of neuropeptide genes including vasopressin and oxytocin [PMID:8543156, PMID:8543155], and it sits downstream of SIM1 to control oxytocin expression [PMID:26833329]. In cortical and stem-cell neurogenesis it governs progenitor proliferative capacity and the switch from direct to indirect neurogenesis, suppressing the Notch effector Hes5 while promoting Tbr2/Tbr1 and acting through direct targets including Zic1, NTF3, SOX2, SOX13 and ADNP [PMID:22892427, PMID:25991548, PMID:29549646, PMID:35245119, PMID:40498903, PMID:39271675]. In Schwann cells it functions redundantly with Oct-6 to drive the promyelinating-to-myelinating transition by directly activating a Krox20 enhancer in synergy with Sox10 [PMID:12782656, PMID:16311519]. Mechanistically, BRN2 binds DNA through its POU domain, can homodimerize on palindromic MORE-type elements, and its activity is tuned by phosphorylation within the POU domain (T361/S362), which switches its transcriptional output between proliferative and migratory programs [PMID:14741405, PMID:22290434]. In melanoma, BRN2 integrates BRAF/MAPK, Wnt/β-catenin, PI3K-Pax3, and CDKN2A-E2F1 inputs and occupies thousands of genomic loci, where it directly represses MITF and CDH13 and activates an invasive program partly through an NFIB-EZH2 axis and KIT-ligand signaling [PMID:15024080, PMID:15024079, PMID:22988297, PMID:29990501, PMID:18829533, PMID:23069940, PMID:28119061]. The BRN2/PAX3 balance forms a rheostat setting MITF plasticity during MAPK inhibition, and BRN2 also induces PTEN to restrain PI3K signaling, giving it a context-dependent tumor-suppressive role [PMID:30277012, PMID:34140478]. Beyond transcription, BRN2 performs a non-transcriptional function at sites of DNA damage, binding PARP1 and Ku70/Ku80, promoting Ku80 recruitment and error-prone non-homologous end-joining while suppressing apoptosis [PMID:30804224]. BRN2 is also required for neuroendocrine differentiation programs in prostate and small-cell lung cancers downstream of androgen receptor suppression [PMID:27784708, PMID:23530560]. Loss-of-function POU3F2 mutations are found in individuals with autism spectrum disorder [PMID:40498903].","teleology":[{"year":1995,"claim":"Established BRN2 as a genetically required factor for terminal differentiation of hypothalamic neurosecretory neurons, defining its developmental role in vivo.","evidence":"Germline gene knockout in mice with histology and neuropeptide gene expression analysis","pmids":["8543156","8543155"],"confidence":"High","gaps":["Direct transcriptional targets at the neuropeptide loci not defined","Did not establish whether the requirement is cell-autonomous"]},{"year":1993,"claim":"Showed BRN2 is required to establish neural cell lineages rather than merely refine them, since its loss diverts embryonal carcinoma cells to non-neural fates.","evidence":"Antisense RNA inhibition in P19 cells with lineage marker analysis","pmids":["8274283"],"confidence":"Medium","gaps":["No direct target genes identified","Antisense specificity not orthogonally confirmed"]},{"year":2003,"claim":"Defined BRN2 as functionally redundant with Oct-6 in driving Schwann cell myelination, resolving how POU-III factors cooperate in peripheral glia.","evidence":"Transgenic overexpression rescue in Oct-6 knockout and compound knockout in mice","pmids":["12782656"],"confidence":"High","gaps":["Did not identify the direct enhancer targets driving the transition (addressed later)"]},{"year":2006,"claim":"Placed BRN2 directly upstream of Krox20 in the myelination hierarchy by identifying a bound enhancer element and Sox10 synergy.","evidence":"Reporter assays, transgenic enhancer analysis and TF binding studies","pmids":["16311519"],"confidence":"High","gaps":["Stoichiometry of BRN2/Oct-6/Sox10 occupancy not resolved"]},{"year":2000,"claim":"Defined BRN2's biochemical interaction repertoire, showing homodimerization via homeodomain/linker and low-affinity contacts with general and melanocyte transcription factors.","evidence":"GAL4-VP16 two-hybrid, GST-pulldown and EMSA with melanoma nuclear extracts","pmids":["11029584"],"confidence":"Medium","gaps":["Functional consequence of TBP/p300/Sox10/Pax3 contacts not established","In vitro affinities not validated in cells"]},{"year":2004,"claim":"Identified BRN2 as a downstream effector of both BRAF/MAPK and Wnt/β-catenin signaling driving melanoma proliferation, integrating two oncogenic inputs at a single transcription factor.","evidence":"Promoter reporter assays, siRNA knockdown and transgenic mice with proliferation assays","pmids":["15024080","15024079"],"confidence":"High","gaps":["Downstream proliferative targets of BRN2 not enumerated in these studies"]},{"year":2008,"claim":"Revealed BRN2 as a regulator of melanoma heterogeneity by directly repressing MITF, with the two factors marking mutually exclusive tumor subpopulations.","evidence":"Promoter reporter assays, siRNA knockdown and biopsy immunohistochemistry","pmids":["18829533"],"confidence":"Medium","gaps":["Mechanism of switching between BRN2-high and MITF-high states not defined"]},{"year":2010,"claim":"Mapped BRN2's genome-wide occupancy in melanoma (~2108 loci), establishing it as a broad regulator including direct control of MITF and KIT-ligand signaling.","evidence":"ChIP-chip occupancy profiling with luciferase reporter validation","pmids":["20337985"],"confidence":"Medium","gaps":["Functional consequence validated only for Kitl","ChIP-chip lower resolution than later ChIP-seq"]},{"year":2012,"claim":"Showed BRN2 transcriptional output is switched by POU-domain phosphorylation at T361/S362, explaining how one factor toggles between proliferation and migration programs.","evidence":"Point mutagenesis with transgenic mouse and in vitro phenotypic assays","pmids":["22290434"],"confidence":"High","gaps":["Kinase responsible for T361/S362 phosphorylation not identified","Structural basis of the phospho-switch unresolved"]},{"year":2012,"claim":"Connected upstream PI3K-Pax3 signaling and downstream CDH13 repression to BRN2, extending its melanoma invasion circuitry.","evidence":"Promoter binding/EMSA, PI3K inhibition, siRNA knockdown and invasion assays","pmids":["22988297","23069940"],"confidence":"Medium","gaps":["Cross-talk between PI3K-Pax3 and MAPK inputs not integrated"]},{"year":2013,"claim":"Established BRN2 as a high-level driver of neuroendocrine differentiation in small-cell lung cancer, upstream of ASCL1/ND1 and directly activating TTF1.","evidence":"siRNA knockdown, ectopic expression, ChIP and cell-cycle assays in SCLC cells","pmids":["23530560","23358112"],"confidence":"Medium","gaps":["Direct vs indirect regulation of ASCL1/ND1 not fully separated"]},{"year":2015,"claim":"Used integrated ChIP-seq/RNA-seq to define a direct BRN2-Zic1 axis required for neuronal fate specification in differentiating ESCs.","evidence":"shRNA knockdown with RNA-seq, ChIP-seq and differentiation assays","pmids":["25991548"],"confidence":"High","gaps":["Zic1 may be one of several effectors; full direct target set not parsed"]},{"year":2016,"claim":"Embedded BRN2 in a β-catenin/Brn2/Tbr2 cascade controlling basal progenitor expansion and linked its deregulation to behavioral abnormalities rescuable by Wnt activation.","evidence":"Dvl mutant mouse model with pharmacological Wnt activation and SIM1-epistasis zebrafish models","pmids":["26830142","26833329"],"confidence":"Medium","gaps":["Direct vs indirect position of BRN2 within the β-catenin/Tbr2 cascade not fully resolved"]},{"year":2017,"claim":"Identified the BRN2-NFIB-EZH2-MITF axis as a mechanism by which BRN2 epigenetically suppresses MITF to promote invasive, low-proliferative melanoma states.","evidence":"Overexpression/siRNA knockdown with migration/invasion and expression assays","pmids":["28119061"],"confidence":"Medium","gaps":["Direct vs indirect induction of NFIB not distinguished"]},{"year":2018,"claim":"Placed BRN2 downstream of androgen-receptor suppression and CDKN2A-E2F1, establishing it as a driver of neuroendocrine prostate differentiation and melanoma metastasis initiation.","evidence":"ChIP of AR/E2F1 at BRN2 promoter, CRISPR-engineered primary cells, xenograft and in vivo rescue","pmids":["27784708","29990501","30277012"],"confidence":"High","gaps":["How BRN2 selects invasion vs differentiation programs across tissues not defined"]},{"year":2019,"claim":"Uncovered a non-transcriptional role for BRN2 at DNA damage sites, where it binds PARP1 and Ku70/80 to promote error-prone NHEJ and suppress apoptosis.","evidence":"Reciprocal Co-IP, live-cell damage recruitment, NHEJ/HR repair assays and apoptosis assays","pmids":["30804224"],"confidence":"High","gaps":["Whether DNA-binding domain or POU domain mediates the repair function unclear","Link between transcriptional and repair functions not integrated"]},{"year":2021,"claim":"Revealed BRN2's behavior on mitotic chromatin, binding condensed chromosomes non-sequence-specifically to enable early transcriptional reactivation of targets like Nestin during mitotic exit.","evidence":"Live-cell imaging, ChIP-seq, single-molecule RNA-FISH and mitotic dominant-negative","pmids":["34168041"],"confidence":"High","gaps":["How non-specific mitotic binding transitions to specific G1 occupancy unresolved"]},{"year":2021,"claim":"Demonstrated a context-dependent tumor-suppressive function whereby BRN2 directly induces PTEN to restrain PI3K signaling, opposing its pro-invasive activity.","evidence":"Conditional knockout mouse models with promoter binding and PI3K signaling analysis","pmids":["34140478"],"confidence":"Medium","gaps":["Determinants of pro- versus anti-tumor BRN2 output not defined"]},{"year":2024,"claim":"Extended BRN2's neurogenic function to primate and cross-species cortical development, controlling radial glia expansion and the direct-to-indirect neurogenesis switch via SOX2/STAT3/HOPX and NOTCH interplay.","evidence":"Biallelic CRISPR knockout in cynomolgus monkeys and conditional knockouts in mice/ferrets with single-cell transcriptomics","pmids":["35245119","39271675"],"confidence":"High","gaps":["Primate-specific regulatory mechanisms not fully dissected at the cis level"]},{"year":2025,"claim":"Linked POU3F2 loss-of-function to autism via reduced Wnt signaling and premature radial glia specification, identifying SOX13 and ADNP as direct mediating targets.","evidence":"CRISPR disruption in human NPCs with RNA-seq, ChIP-seq and Wnt reporter assays","pmids":["40498903"],"confidence":"Medium","gaps":["Genotype-phenotype correlation in patients not established","Single-lab human NPC model"]},{"year":null,"claim":"How BRN2 integrates its sequence-specific transcriptional, mitotic-bookmarking, and DNA-repair activities into a unified control of cell fate and survival remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model linking POU-domain DNA binding to PARP1/Ku association","Kinases and signals that select among BRN2's divergent outputs are unmapped","Whether DNA-repair function operates outside melanoma is untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,3,6,11,24,27]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[9,12,21,29]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[7,11,29]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[29]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[3,6,24,27]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[0,2,23,37,38]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[4,13,15,33,39]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[14,31]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[5,10,16]}],"complexes":[],"partners":["PARP1","XRCC6","XRCC5","PAX3","SOX10","NFYB","ARNT2","PQBP1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P20265","full_name":"POU domain, class 3, transcription factor 2","aliases":["Brain-specific homeobox/POU domain protein 2","Brain-2","Brn-2","Nervous system-specific octamer-binding transcription factor N-Oct-3","Octamer-binding protein 7","Oct-7","Octamer-binding transcription factor 7","OTF-7"],"length_aa":443,"mass_kda":46.9,"function":"Transcription factor that plays a key role in neuronal differentiation (By similarity). Binds preferentially to the recognition sequence which consists of two distinct half-sites, ('GCAT') and ('TAAT'), separated by a non-conserved spacer region of 0, 2, or 3 nucleotides (By similarity). Acts as a transcriptional activator when binding cooperatively with SOX4, SOX11, or SOX12 to gene promoters (By similarity). The combination of three transcription factors, ASCL1, POU3F2/BRN2 and MYT1L, is sufficient to reprogram fibroblasts and other somatic cells into induced neuronal (iN) cells in vitro (By similarity). Acts downstream of ASCL1, accessing chromatin that has been opened by ASCL1, and promotes transcription of neuronal genes (By similarity)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/P20265/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/POU3F2","classification":"Not Classified","n_dependent_lines":5,"n_total_lines":1208,"dependency_fraction":0.0041390728476821195},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/POU3F2","total_profiled":1310},"omim":[{"mim_id":"613084","title":"MYELIN TRANSCRIPTION FACTOR 1-LIKE; MYT1L","url":"https://www.omim.org/entry/613084"},{"mim_id":"606582","title":"DELTA-LIKE CANONICAL NOTCH LIGAND 1; DLL1","url":"https://www.omim.org/entry/606582"},{"mim_id":"602480","title":"POU DOMAIN, CLASS 3, TRANSCRIPTION FACTOR 3; POU3F3","url":"https://www.omim.org/entry/602480"},{"mim_id":"602479","title":"POU DOMAIN, CLASS 3, TRANSCRIPTION FACTOR 1; POU3F1","url":"https://www.omim.org/entry/602479"},{"mim_id":"602192","title":"A DISINTEGRIN AND METALLOPROTEINASE DOMAIN 10; ADAM10","url":"https://www.omim.org/entry/602192"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in single","driving_tissues":[{"tissue":"brain","ntpm":11.1}],"url":"https://www.proteinatlas.org/search/POU3F2"},"hgnc":{"alias_symbol":["POUF3","BRN2","OCT7"],"prev_symbol":["OTF7"]},"alphafold":{"accession":"P20265","domains":[{"cath_id":"1.10.260.40","chopping":"266-349","consensus_level":"high","plddt":86.5202,"start":266,"end":349},{"cath_id":"1.10.10.60","chopping":"362-411","consensus_level":"high","plddt":95.1786,"start":362,"end":411}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P20265","model_url":"https://alphafold.ebi.ac.uk/files/AF-P20265-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P20265-F1-predicted_aligned_error_v6.png","plddt_mean":60.91},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=POU3F2","jax_strain_url":"https://www.jax.org/strain/search?query=POU3F2"},"sequence":{"accession":"P20265","fasta_url":"https://rest.uniprot.org/uniprotkb/P20265.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P20265/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P20265"}},"corpus_meta":[{"pmid":"27784708","id":"PMC_27784708","title":"The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.","date":"2016","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/27784708","citation_count":355,"is_preprint":false},{"pmid":"8543156","id":"PMC_8543156","title":"Development and survival of the endocrine hypothalamus and posterior pituitary gland requires the neuronal POU domain factor Brn-2.","date":"1995","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/8543156","citation_count":247,"is_preprint":false},{"pmid":"12782656","id":"PMC_12782656","title":"The POU proteins Brn-2 and Oct-6 share important functions in Schwann cell development.","date":"2003","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/12782656","citation_count":240,"is_preprint":false},{"pmid":"8543155","id":"PMC_8543155","title":"The POU domain transcription factor Brn-2 is required for the determination of specific neuronal lineages in the hypothalamus of the mouse.","date":"1995","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/8543155","citation_count":230,"is_preprint":false},{"pmid":"19826052","id":"PMC_19826052","title":"Intravital imaging reveals transient changes in pigment production and Brn2 expression during metastatic melanoma dissemination.","date":"2009","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19826052","citation_count":168,"is_preprint":false},{"pmid":"22892427","id":"PMC_22892427","title":"POU-III transcription factors (Brn1, Brn2, and Oct6) influence neurogenesis, molecular identity, and migratory destination of upper-layer cells of the cerebral cortex.","date":"2012","source":"Cerebral cortex (New York, N.Y. : 1991)","url":"https://pubmed.ncbi.nlm.nih.gov/22892427","citation_count":162,"is_preprint":false},{"pmid":"10332029","id":"PMC_10332029","title":"PQBP-1, a novel polyglutamine tract-binding protein, inhibits transcription activation by Brn-2 and affects cell survival.","date":"1999","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10332029","citation_count":160,"is_preprint":false},{"pmid":"18829533","id":"PMC_18829533","title":"Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor-negative melanoma cells.","date":"2008","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/18829533","citation_count":159,"is_preprint":false},{"pmid":"21435193","id":"PMC_21435193","title":"Melanoma cell invasiveness is regulated by miR-211 suppression of the BRN2 transcription factor.","date":"2011","source":"Pigment cell & melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/21435193","citation_count":150,"is_preprint":false},{"pmid":"16311519","id":"PMC_16311519","title":"Control of myelination in Schwann cells: a Krox20 cis-regulatory element integrates Oct6, Brn2 and Sox10 activities.","date":"2006","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/16311519","citation_count":144,"is_preprint":false},{"pmid":"29990501","id":"PMC_29990501","title":"Bi-allelic Loss of CDKN2A Initiates Melanoma Invasion via BRN2 Activation.","date":"2018","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/29990501","citation_count":105,"is_preprint":false},{"pmid":"15024080","id":"PMC_15024080","title":"The Brn-2 transcription factor links activated BRAF to melanoma proliferation.","date":"2004","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15024080","citation_count":97,"is_preprint":false},{"pmid":"15024079","id":"PMC_15024079","title":"Brn-2 expression controls melanoma proliferation and is directly regulated by beta-catenin.","date":"2004","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15024079","citation_count":95,"is_preprint":false},{"pmid":"14708619","id":"PMC_14708619","title":"Human melanoblasts in culture: expression of BRN2 and synergistic regulation by fibroblast growth factor-2, stem cell factor, and endothelin-3.","date":"2003","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/14708619","citation_count":83,"is_preprint":false},{"pmid":"30545964","id":"PMC_30545964","title":"The transcription factor POU3F2 regulates a gene coexpression network in brain tissue from patients with psychiatric disorders.","date":"2018","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30545964","citation_count":79,"is_preprint":false},{"pmid":"8274283","id":"PMC_8274283","title":"A CNS-specific POU transcription factor, Brn-2, is required for establishing mammalian neural cell lineages.","date":"1993","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/8274283","citation_count":78,"is_preprint":false},{"pmid":"21358674","id":"PMC_21358674","title":"Inverse expression states of the BRN2 and MITF transcription factors in melanoma spheres and tumour xenografts regulate the NOTCH pathway.","date":"2011","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/21358674","citation_count":76,"is_preprint":false},{"pmid":"28119061","id":"PMC_28119061","title":"NFIB Mediates BRN2 Driven Melanoma Cell Migration and Invasion Through Regulation of EZH2 and MITF.","date":"2017","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/28119061","citation_count":72,"is_preprint":false},{"pmid":"31371344","id":"PMC_31371344","title":"BRN4 Is a Novel Driver of Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer and Is Selectively Released in Extracellular Vesicles with BRN2.","date":"2019","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/31371344","citation_count":67,"is_preprint":false},{"pmid":"7651733","id":"PMC_7651733","title":"The brn-2 gene regulates the melanocytic phenotype and tumorigenic potential of human melanoma cells.","date":"1995","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/7651733","citation_count":67,"is_preprint":false},{"pmid":"26830142","id":"PMC_26830142","title":"Prenatal β-catenin/Brn2/Tbr2 transcriptional cascade regulates adult social and stereotypic behaviors.","date":"2016","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/26830142","citation_count":65,"is_preprint":false},{"pmid":"18983536","id":"PMC_18983536","title":"POU domain transcription factors: BRN2 as a regulator of melanocytic growth and tumourigenesis.","date":"2008","source":"Pigment cell & melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/18983536","citation_count":54,"is_preprint":false},{"pmid":"28883623","id":"PMC_28883623","title":"MITF and BRN2 contribute to metastatic growth after dissemination of melanoma.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28883623","citation_count":48,"is_preprint":false},{"pmid":"20337985","id":"PMC_20337985","title":"Genome-wide analysis of POU3F2/BRN2 promoter occupancy in human melanoma cells reveals Kitl as a novel regulated target gene.","date":"2010","source":"Pigment cell & melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/20337985","citation_count":48,"is_preprint":false},{"pmid":"29781575","id":"PMC_29781575","title":"BRN2, a POUerful driver of melanoma phenotype switching and metastasis.","date":"2018","source":"Pigment cell & melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/29781575","citation_count":46,"is_preprint":false},{"pmid":"23530560","id":"PMC_23530560","title":"POU domain transcription factor BRN2 is crucial for expression of ASCL1, ND1 and neuroendocrine marker molecules and cell growth in small cell lung cancer.","date":"2013","source":"Pathology international","url":"https://pubmed.ncbi.nlm.nih.gov/23530560","citation_count":46,"is_preprint":false},{"pmid":"22988297","id":"PMC_22988297","title":"A phosphatidylinositol 3-kinase-Pax3 axis regulates Brn-2 expression in melanoma.","date":"2012","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/22988297","citation_count":42,"is_preprint":false},{"pmid":"20185558","id":"PMC_20185558","title":"Mutant huntingtin fragment selectively suppresses Brn-2 POU domain transcription factor to mediate hypothalamic cell dysfunction.","date":"2010","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20185558","citation_count":41,"is_preprint":false},{"pmid":"18923447","id":"PMC_18923447","title":"SOX9 and SOX10 but not BRN2 are required for nestin expression in human melanoma cells.","date":"2008","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/18923447","citation_count":40,"is_preprint":false},{"pmid":"11029584","id":"PMC_11029584","title":"Domains of Brn-2 that mediate homodimerization and interaction with general and melanocytic transcription factors.","date":"2000","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11029584","citation_count":40,"is_preprint":false},{"pmid":"26833329","id":"PMC_26833329","title":"Small 6q16.1 Deletions Encompassing POU3F2 Cause Susceptibility to Obesity and Variable Developmental Delay with Intellectual Disability.","date":"2016","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26833329","citation_count":37,"is_preprint":false},{"pmid":"9106466","id":"PMC_9106466","title":"Predominant expression of Brn-2 in the postmitotic neurons of the developing mouse neocortex.","date":"1997","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/9106466","citation_count":36,"is_preprint":false},{"pmid":"8593698","id":"PMC_8593698","title":"Preferential differentiation of P19 mouse embryonal carcinoma cells into smooth muscle cells. Use of retinoic acid and antisense against the central nervous system-specific POU transcription factor Brn-2.","date":"1996","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/8593698","citation_count":36,"is_preprint":false},{"pmid":"29549646","id":"PMC_29549646","title":"NTF3 Is a Novel Target Gene of the Transcription Factor POU3F2 and Is Required for Neuronal Differentiation.","date":"2018","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/29549646","citation_count":35,"is_preprint":false},{"pmid":"30277012","id":"PMC_30277012","title":"A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITFhigh /AXLlow melanoma.","date":"2018","source":"Pigment cell & melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/30277012","citation_count":34,"is_preprint":false},{"pmid":"12213447","id":"PMC_12213447","title":"Expression of the POU-domain transcription factors SCIP/Oct-6 and Brn-2 is associated with Schwann cell but not oligodendrocyte remyelination of the CNS.","date":"2002","source":"Molecular and cellular neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/12213447","citation_count":33,"is_preprint":false},{"pmid":"30804224","id":"PMC_30804224","title":"BRN2 suppresses apoptosis, reprograms DNA damage repair, and is associated with a high somatic mutation burden in melanoma.","date":"2019","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/30804224","citation_count":32,"is_preprint":false},{"pmid":"30029680","id":"PMC_30029680","title":"Regulation of tNOX expression through the ROS-p53-POU3F2 axis contributes to cellular responses against oxaliplatin in human colon cancer cells.","date":"2018","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/30029680","citation_count":29,"is_preprint":false},{"pmid":"28782255","id":"PMC_28782255","title":"POU3F2 participates in cognitive function and adult hippocampal neurogenesis via mammalian-characteristic amino acid repeats.","date":"2017","source":"Genes, brain, and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/28782255","citation_count":27,"is_preprint":false},{"pmid":"23358112","id":"PMC_23358112","title":"Neural lineage-specific homeoprotein BRN2 is directly involved in TTF1 expression in small-cell lung cancer.","date":"2013","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/23358112","citation_count":27,"is_preprint":false},{"pmid":"31920461","id":"PMC_31920461","title":"LncRNA BCYRN1/miR-490-3p/POU3F2, served as a ceRNA network, is connected with worse survival rate of hepatocellular carcinoma patients and promotes tumor cell growth and metastasis.","date":"2020","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/31920461","citation_count":27,"is_preprint":false},{"pmid":"32632141","id":"PMC_32632141","title":"BRN2 expression increases anoikis resistance in melanoma.","date":"2020","source":"Oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/32632141","citation_count":26,"is_preprint":false},{"pmid":"32929213","id":"PMC_32929213","title":"Transcription factor POU3F2 regulates TRIM8 expression contributing to cellular functions implicated in schizophrenia.","date":"2020","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/32929213","citation_count":26,"is_preprint":false},{"pmid":"33513758","id":"PMC_33513758","title":"Integrin α3β1 Promotes Invasive and Metastatic Properties of Breast Cancer Cells through Induction of the Brn-2 Transcription Factor.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/33513758","citation_count":26,"is_preprint":false},{"pmid":"7601453","id":"PMC_7601453","title":"Isolation of the human genomic brain-2/N-Oct 3 gene (POUF3) and assignment to chromosome 6q16.","date":"1995","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/7601453","citation_count":25,"is_preprint":false},{"pmid":"29635978","id":"PMC_29635978","title":"Brn2 Alone Is Sufficient to Convert Astrocytes into Neural Progenitors and Neurons.","date":"2018","source":"Stem cells and development","url":"https://pubmed.ncbi.nlm.nih.gov/29635978","citation_count":25,"is_preprint":false},{"pmid":"25991548","id":"PMC_25991548","title":"A Brn2-Zic1 axis specifies the neuronal fate of retinoic-acid-treated embryonic stem cells.","date":"2015","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/25991548","citation_count":25,"is_preprint":false},{"pmid":"32169117","id":"PMC_32169117","title":"MicroRNA-107 is a novel tumor suppressor targeting POU3F2 in melanoma.","date":"2020","source":"Biological research","url":"https://pubmed.ncbi.nlm.nih.gov/32169117","citation_count":23,"is_preprint":false},{"pmid":"23069940","id":"PMC_23069940","title":"BRN2 is a transcriptional repressor of CDH13 (T-cadherin) in melanoma cells.","date":"2012","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/23069940","citation_count":23,"is_preprint":false},{"pmid":"15911144","id":"PMC_15911144","title":"The neuronal POU transcription factor Brn-2 interacts with Jab1, a gene involved in the onset of neurodegenerative diseases.","date":"2005","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/15911144","citation_count":23,"is_preprint":false},{"pmid":"10446900","id":"PMC_10446900","title":"A requirement for the POU transcription factor, Brn-2, in corticotropin-releasing hormone expression in a neuronal cell line.","date":"1999","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/10446900","citation_count":23,"is_preprint":false},{"pmid":"16858508","id":"PMC_16858508","title":"Exclusion of mutations in the PRNP, JPH3, TBP, ATN1, CREBBP, POU3F2 and FTL genes as a cause of disease in Portuguese patients with a Huntington-like phenotype.","date":"2006","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16858508","citation_count":22,"is_preprint":false},{"pmid":"22290434","id":"PMC_22290434","title":"Phosphorylation of BRN2 modulates its interaction with the Pax3 promoter to control melanocyte migration and proliferation.","date":"2012","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/22290434","citation_count":22,"is_preprint":false},{"pmid":"32973101","id":"PMC_32973101","title":"A Novel miR-146a-POU3F2/SMARCA5 Pathway Regulates Stemness and Therapeutic Response in Glioblastoma.","date":"2020","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/32973101","citation_count":21,"is_preprint":false},{"pmid":"34168041","id":"PMC_34168041","title":"Hierarchical reactivation of transcription during mitosis-to-G1 transition by Brn2 and Ascl1 in neural stem cells.","date":"2021","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/34168041","citation_count":21,"is_preprint":false},{"pmid":"18781132","id":"PMC_18781132","title":"Histologic and epidemiologic correlates of P-MAPK, Brn-2, pRb, p53, and p16 immunostaining in cutaneous melanomas.","date":"2008","source":"Melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/18781132","citation_count":20,"is_preprint":false},{"pmid":"38386071","id":"PMC_38386071","title":"RFX4 is an intrinsic factor for neuronal differentiation through induction of proneural genes POU3F2 and NEUROD1.","date":"2024","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/38386071","citation_count":19,"is_preprint":false},{"pmid":"27271588","id":"PMC_27271588","title":"Capsaicin Inhibited Aggressive Phenotypes through Downregulation of Tumor-Associated NADH Oxidase (tNOX) by POU Domain Transcription Factor POU3F2.","date":"2016","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/27271588","citation_count":19,"is_preprint":false},{"pmid":"31807777","id":"PMC_31807777","title":"Phosphorylation of Tet3 by cdk5 is critical for robust activation of BRN2 during neuronal differentiation.","date":"2020","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/31807777","citation_count":18,"is_preprint":false},{"pmid":"17163992","id":"PMC_17163992","title":"Rb induces a proliferative arrest and curtails Brn-2 expression in retinoblastoma cells.","date":"2006","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17163992","citation_count":17,"is_preprint":false},{"pmid":"24709564","id":"PMC_24709564","title":"Mammalian-specific sequences in pou3f2 contribute to maternal behavior.","date":"2014","source":"Genome biology and evolution","url":"https://pubmed.ncbi.nlm.nih.gov/24709564","citation_count":16,"is_preprint":false},{"pmid":"33531841","id":"PMC_33531841","title":"Circ_0031242 Silencing Mitigates the Progression and Drug Resistance in DDP-Resistant Hepatoma Cells by the miR-924/POU3F2 Axis.","date":"2021","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/33531841","citation_count":15,"is_preprint":false},{"pmid":"11311976","id":"PMC_11311976","title":"NF-Y binding is required for transactivation of neuronal aromatic L-amino acid decarboxylase gene promoter by the POU-domain protein Brn-2.","date":"2001","source":"Brain research. Molecular brain research","url":"https://pubmed.ncbi.nlm.nih.gov/11311976","citation_count":15,"is_preprint":false},{"pmid":"39271675","id":"PMC_39271675","title":"Conserved transcriptional regulation by BRN1 and BRN2 in neocortical progenitors drives mammalian neural specification and neocortical expansion.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39271675","citation_count":14,"is_preprint":false},{"pmid":"34140478","id":"PMC_34140478","title":"BRN2 is a non-canonical melanoma tumor-suppressor.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34140478","citation_count":13,"is_preprint":false},{"pmid":"30199896","id":"PMC_30199896","title":"A De Novo Missense Variant in POU3F2 Identified in a Child with Global Developmental Delay.","date":"2018","source":"Neuropediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/30199896","citation_count":13,"is_preprint":false},{"pmid":"20967260","id":"PMC_20967260","title":"Brn2 is a transcription factor regulating keratinocyte differentiation with a possible role in the pathogenesis of lichen planus.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20967260","citation_count":13,"is_preprint":false},{"pmid":"35245119","id":"PMC_35245119","title":"BRN2 as a key gene drives the early primate telencephalon development.","date":"2022","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/35245119","citation_count":11,"is_preprint":false},{"pmid":"36797433","id":"PMC_36797433","title":"Overexpression of POU3F2 promotes radioresistance in triple-negative breast cancer via Akt pathway activation.","date":"2023","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/36797433","citation_count":11,"is_preprint":false},{"pmid":"36843258","id":"PMC_36843258","title":"Integrin α3 Mediates Stemness and Invasion of Glioblastoma by Regulating POU3F2.","date":"2023","source":"Current protein & peptide science","url":"https://pubmed.ncbi.nlm.nih.gov/36843258","citation_count":10,"is_preprint":false},{"pmid":"37207645","id":"PMC_37207645","title":"Monoallelic intragenic POU3F2 variants lead to neurodevelopmental delay and hyperphagic obesity, confirming the gene's candidacy in 6q16.1 deletions.","date":"2023","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/37207645","citation_count":8,"is_preprint":false},{"pmid":"39756795","id":"PMC_39756795","title":"The promoting effect of the POU3F2/METTL16/PFKM cascade on glycolysis and tumorigenesis of hepatocellular carcinoma.","date":"2025","source":"Annals of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/39756795","citation_count":8,"is_preprint":false},{"pmid":"28648603","id":"PMC_28648603","title":"Effects of Brn2 overexpression on eccrine sweat gland development in the mouse paw.","date":"2017","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/28648603","citation_count":7,"is_preprint":false},{"pmid":"30417795","id":"PMC_30417795","title":"Peptide R18H from BRN2 Transcription Factor POU Domain Displays Antitumor Activity In Vitro and In Vivo and Induces Apoptosis in B16F10-Nex2 Cells.","date":"2019","source":"Anti-cancer agents in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30417795","citation_count":7,"is_preprint":false},{"pmid":"38201271","id":"PMC_38201271","title":"CREB1 Facilitates GABAergic Neural Differentiation of Human Mesenchymal Stem Cells through BRN2 for Pain Alleviation and Locomotion Recovery after Spinal Cord Injury.","date":"2023","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/38201271","citation_count":6,"is_preprint":false},{"pmid":"26555748","id":"PMC_26555748","title":"Partial Dedifferentiation of Murine Radial Glia-Type Neural Stem Cells by Brn2 and c-Myc Yields Early Neuroepithelial Progenitors.","date":"2015","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/26555748","citation_count":6,"is_preprint":false},{"pmid":"33119145","id":"PMC_33119145","title":"BRN2 and MITF together impact AXL expression in melanoma.","date":"2020","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/33119145","citation_count":5,"is_preprint":false},{"pmid":"35398178","id":"PMC_35398178","title":"CircPOLR2A Promotes Proliferation and Impedes Apoptosis of Glioblastoma Multiforme Cells by Up-regulating POU3F2 to Facilitate SOX9 Transcription.","date":"2022","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/35398178","citation_count":5,"is_preprint":false},{"pmid":"12644309","id":"PMC_12644309","title":"Adenoviral-mediated over-expression of Brn2 in the rat paraventricular nucleus: no effect on vasopressin or corticotrophin releasing factor RNA levels.","date":"2003","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/12644309","citation_count":5,"is_preprint":false},{"pmid":"14741405","id":"PMC_14741405","title":"Cooperative dimerization of the POU domain protein Brn-2 on a new motif activates the neuronal promoter of the human aromatic L-amino acid decarboxylase gene.","date":"2004","source":"Brain research. Molecular brain research","url":"https://pubmed.ncbi.nlm.nih.gov/14741405","citation_count":5,"is_preprint":false},{"pmid":"9706393","id":"PMC_9706393","title":"Transcriptional regulatory region of Brn-2 required for its expression in developing olfactory epithelial cells.","date":"1998","source":"Brain research. Developmental brain research","url":"https://pubmed.ncbi.nlm.nih.gov/9706393","citation_count":5,"is_preprint":false},{"pmid":"27568376","id":"PMC_27568376","title":"In silico studies of the interaction between BRN2 protein and MORE DNA.","date":"2016","source":"Journal of molecular modeling","url":"https://pubmed.ncbi.nlm.nih.gov/27568376","citation_count":4,"is_preprint":false},{"pmid":"35306097","id":"PMC_35306097","title":"Deficient maternal behavior in multiparous Pou3f2⊿ mice is associated with an impaired exploratory activity.","date":"2022","source":"Behavioural brain research","url":"https://pubmed.ncbi.nlm.nih.gov/35306097","citation_count":4,"is_preprint":false},{"pmid":"28285791","id":"PMC_28285791","title":"Immunohistochemical study of the neural development transcription factors (TTF1, ASCL1 and BRN2) in neuroendocrine prostate tumours.","date":"2017","source":"Actas urologicas espanolas","url":"https://pubmed.ncbi.nlm.nih.gov/28285791","citation_count":4,"is_preprint":false},{"pmid":"28855426","id":"PMC_28855426","title":"Neural differentiation of fibroblasts induced by intracellular co-delivery of Ascl1, Brn2 and FoxA1 via a non-viral vector of cationic polysaccharide.","date":"2017","source":"Biomedical materials (Bristol, England)","url":"https://pubmed.ncbi.nlm.nih.gov/28855426","citation_count":4,"is_preprint":false},{"pmid":"40498903","id":"PMC_40498903","title":"POU3F2 regulates canonical Wnt signalling via SOX13 and ADNP to expand the neural progenitor population.","date":"2025","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/40498903","citation_count":3,"is_preprint":false},{"pmid":"34958806","id":"PMC_34958806","title":"Reciprocal Regulation of BRN2 and NOTCH1/2 Signaling Synergistically Drives Melanoma Cell Migration and Invasion.","date":"2021","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/34958806","citation_count":3,"is_preprint":false},{"pmid":"39822524","id":"PMC_39822524","title":"Neuroendocrine prostate cancer drivers SOX2 and BRN2 confer differential responses to imipridones ONC201, ONC206, and ONC212 in prostate cancer cell lines.","date":"2024","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/39822524","citation_count":2,"is_preprint":false},{"pmid":"38160013","id":"PMC_38160013","title":"Peptide L13S Derived from the BRN2 POU Domain Reduces Metastasis In Vivo and Inhibits Cell Migration and Invasion In Vitro.","date":"2024","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/38160013","citation_count":1,"is_preprint":false},{"pmid":"41961819","id":"PMC_41961819","title":"Resistance to neoadjuvant talazoparib in triple-negative breast cancer by BRN2-induced ATR/STAT3 pathways or SHLD2 subclone expansion.","date":"2026","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/41961819","citation_count":1,"is_preprint":false},{"pmid":"41405996","id":"PMC_41405996","title":"A BRN2:MYC transcriptional axis regulates interconversion between therapy-resistant and tumorigenic phenotypes in melanoma.","date":"2025","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/41405996","citation_count":0,"is_preprint":false},{"pmid":"39257809","id":"PMC_39257809","title":"Neuroendocrine Prostate Cancer Drivers SOX2 and BRN2 Confer Differential Responses to Imipridones ONC201, ONC206, and ONC212 in Prostate Cancer Cell Lines.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/39257809","citation_count":0,"is_preprint":false},{"pmid":"41952195","id":"PMC_41952195","title":"Transposable element-mediated evolutionary expansion of Sox2- and Brn2-binding regulatory modules for mammalian neural-cell differentiation.","date":"2026","source":"Genome biology","url":"https://pubmed.ncbi.nlm.nih.gov/41952195","citation_count":0,"is_preprint":false},{"pmid":"41763511","id":"PMC_41763511","title":"Reprogramming of astrocytes into motoneuron-like cells by a Ascl1-Myt1l-Pou3f2-Isl1 cocktail.","date":"2026","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/41763511","citation_count":0,"is_preprint":false},{"pmid":"40601014","id":"PMC_40601014","title":"Peptides derived from the POU domain of BRN2 show antitumor activity against murine melanoma model cells in vitro and in vivo.","date":"2025","source":"Cancer chemotherapy and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/40601014","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.07.31.667908","title":"Inhibition of BRN2 in Melanoma Reverses Anoikis Resistance and Sensitizes Cells to Killing by Vemurafenib","date":"2025-08-02","source":"bioRxiv","url":"https://doi.org/10.1101/2025.07.31.667908","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.08.17.670702","title":"Postnatal plasticity in the olfactory system of the juvenile swine brain","date":"2025-08-19","source":"bioRxiv","url":"https://doi.org/10.1101/2025.08.17.670702","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.03.31.646367","title":"Human-chimpanzee tetraploid system defines mechanisms of species-specific neural gene regulation","date":"2025-03-31","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.31.646367","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.06.16.659895","title":"A Comprehensive Analysis of Atlantic Salmon Gonad and Pituitary Transcriptomes Identifies Novel Players in Sexual Maturation","date":"2025-06-20","source":"bioRxiv","url":"https://doi.org/10.1101/2025.06.16.659895","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.06.10.658830","title":"FOXP1 differentially regulates the development of murine vasopressin and oxytocin magnocellular neurons","date":"2025-06-10","source":"bioRxiv","url":"https://doi.org/10.1101/2025.06.10.658830","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49551,"output_tokens":11220,"usd":0.158476,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":22163,"output_tokens":5610,"usd":0.125532,"stage2_stop_reason":"end_turn"},"total_usd":0.284008,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1995,\n      \"finding\": \"Deletion of the Brn-2 genomic locus in mice results in failure of differentiation of paraventricular and supraoptic nucleus neurons, inability to activate neuropeptide-encoding genes (including vasopressin and oxytocin), and failure of correct axonal projections, demonstrating that Brn-2 is required at a penultimate step in hypothalamic neurosecretory neuron differentiation.\",\n      \"method\": \"Gene knockout (homologous recombination in ES cells), histology, gene expression analysis\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two independent knockout studies (PMID:8543156 and PMID:8543155) using gene targeting with concordant phenotypes in multiple labs\",\n      \"pmids\": [\"8543156\", \"8543155\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Antisense RNA-mediated inhibition of Brn-2 induction in P19 embryonal carcinoma cells blocks differentiation into neurons and astrocytes, causing cells to instead differentiate into non-neural cell types (smooth and skeletal muscle), demonstrating that Brn-2 is required for establishing neural cell lineages.\",\n      \"method\": \"Antisense RNA inhibition in P19 cells, morphological and lineage marker analysis\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with defined cellular phenotype and lineage markers, single lab\",\n      \"pmids\": [\"8274283\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Brn-2 is expressed in Schwann cells with a developmental profile similar to Oct-6; overexpression of Brn-2 under the Oct-6 Schwann cell enhancer partially rescues the developmental delay in Oct-6-deficient Schwann cells; compound disruption of both Brn-2 and Oct-6 produces a much more severe myelination phenotype, demonstrating that Brn-2 function largely overlaps with Oct-6 in driving the promyelinating-to-myelinating transition.\",\n      \"method\": \"Transgenic overexpression rescue in Oct-6 knockout, compound knockout, developmental expression profiling\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with rescue and compound knockout, multiple orthogonal approaches in single study\",\n      \"pmids\": [\"12782656\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Oct6 and Brn2 directly activate Krox20 expression in Schwann cells by binding to a defined Krox20 enhancer element during the promyelin-to-myelin transition; Sox10 synergizes with these POU proteins on this enhancer, placing Brn2 directly upstream of Krox20 in the myelination transcriptional hierarchy.\",\n      \"method\": \"Cell culture reporter assays, transgenic enhancer analysis, transcription factor binding studies\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct enhancer binding and reporter assays combined with transgenesis, multiple orthogonal methods in single study\",\n      \"pmids\": [\"16311519\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Brn-2 expression in melanoma is strongly upregulated downstream of Ras and MAPK signaling; the Brn-2 promoter is stimulated by kinase-activating BRAF mutants; siRNA-mediated depletion of BRAF reduces endogenous Brn-2 expression; and siRNA depletion of Brn-2 in BRAF-activated melanoma cells decreases proliferation, placing Brn-2 as a downstream effector of BRAF signaling in melanoma proliferation.\",\n      \"method\": \"Promoter reporter assays, siRNA knockdown, proliferation assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (promoter assays, BRAF knockdown epistasis, Brn-2 knockdown phenotype), replicated across two concurrent publications\",\n      \"pmids\": [\"15024080\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Brn-2 expression is directly controlled by the Wnt/beta-catenin signaling pathway in melanoma cell lines and transgenic mice; siRNA inhibition of Brn-2 in beta-catenin-overexpressing melanoma cells results in decreased proliferation, identifying Brn-2 as a convergence point for BRAF and Wnt/beta-catenin signaling in melanoma proliferation.\",\n      \"method\": \"Promoter reporter assays, siRNA knockdown, transgenic mice, proliferation assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct promoter regulation demonstrated with reporter assays and transgenic validation, functional knockdown phenotype, same lab as PMID:15024080\",\n      \"pmids\": [\"15024079\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Brn-2 directly represses Mitf expression in melanoma cells, and Brn-2 and Mitf mark distinct non-overlapping subpopulations within melanoma biopsies, demonstrating Brn-2 as a regulator of tumor heterogeneity through direct MITF repression.\",\n      \"method\": \"Promoter reporter assays, siRNA knockdown, immunohistochemistry of biopsies\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct promoter repression shown with reporter assays, siRNA knockdown, validated in clinical samples\",\n      \"pmids\": [\"18829533\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"PQBP-1, a novel polyglutamine tract-binding protein, binds directly to the polyglutamine tract of Brn-2 and inhibits Brn-2-mediated transcriptional activation in cells.\",\n      \"method\": \"Protein identification by binding, co-transfection transcriptional assays, nuclear localization studies\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct protein interaction with functional transcriptional inhibition shown, single lab with multiple methods\",\n      \"pmids\": [\"10332029\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Brn-2 homodimerizes in vivo; dimerization requires both the homeodomain and linker regions of the POU domain. Brn-2 also shows low-affinity interactions with TBP, the transcriptional coactivator p300, and with the melanocyte transcription factors Sox-10 and Pax-3.\",\n      \"method\": \"GAL4-VP16 two-hybrid assay, GST-pulldown, EMSA with melanoma nuclear extracts\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple in vitro binding methods (two-hybrid, GST-pulldown, EMSA) in single study, single lab\",\n      \"pmids\": [\"11029584\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Brn-2 directly represses CDH13 (T-cadherin) promoter activity in melanoma cells; BRN2 binds to a specific element at -219 bp of the CDH13 promoter (5'-CATGCAAAA-3'); ectopic BRN2 suppresses CDH13 promoter activity, and BRN2 knockdown restores T-cadherin expression.\",\n      \"method\": \"Reporter gene assays, EMSA, siRNA knockdown, ectopic expression\",\n      \"journal\": \"Laboratory investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct promoter binding and repression demonstrated with EMSA and reporter assays plus functional validation, single lab\",\n      \"pmids\": [\"23069940\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"PI3K signaling positively regulates Brn-2 expression in melanoma via Pax3; Pax3 directly binds and activates the Brn-2 promoter; PI3K inhibition reduces both Pax3 and Brn-2 expression and decreases melanoma invasiveness, placing Brn-2 downstream of a PI3K-Pax3 axis.\",\n      \"method\": \"PI3K inhibitor treatment, promoter binding assays, siRNA knockdown, invasion assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct promoter binding demonstrated, epistasis established via inhibitor and knockdown, single lab\",\n      \"pmids\": [\"22988297\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Phosphorylation of BRN2 at T361 and S362 within the POU domain differentially regulates its transcriptional targets: phosphorylated BRN2 (BRN2TS) induces proliferation and represses migration and activates PAX3 transcription, while non-phosphorylatable BRN2 (BRN2AA) represses both proliferation and migration, and represses PAX3. Both forms repress MITF-M.\",\n      \"method\": \"Point mutagenesis, transgenic mouse models, in vitro cell assays, gene expression analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — active-site mutagenesis validated in both in vitro and transgenic in vivo settings, multiple phenotypic readouts, single lab\",\n      \"pmids\": [\"22290434\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"POU3F2/BRN2 occupies approximately 2108 genomic loci in melanoma cells including the MITF promoter and the Kit ligand (Kitl) proximal promoter; BRN2 regulates Kitl expression via a cluster of four closely spaced binding sites, indicating BRN2 can drive autocrine KIT ligand signaling.\",\n      \"method\": \"ChIP-chip genome-wide occupancy profiling, luciferase reporter assays\",\n      \"journal\": \"Pigment cell & melanoma research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genome-wide ChIP-chip combined with functional reporter validation for Kitl, single lab\",\n      \"pmids\": [\"20337985\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Androgen receptor (AR) directly suppresses BRN2 transcription in prostate cancer; loss of AR activity leads to elevated BRN2 expression; BRN2 is required for neuroendocrine prostate cancer (NEPC) and regulates the NEPC marker SOX2, placing BRN2 downstream of AR suppression as a driver of neuroendocrine differentiation.\",\n      \"method\": \"AR pathway inhibition models, ChIP assays demonstrating direct AR binding to BRN2 promoter, siRNA knockdown, in vitro and xenograft functional assays\",\n      \"journal\": \"Cancer discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct AR binding to BRN2 promoter by ChIP, multiple functional assays in vitro and in vivo, validated in clinical samples\",\n      \"pmids\": [\"27784708\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"BRN2 associates with DNA damage response proteins PARP1 and Ku70/Ku80 (not transcriptional cofactors); BRN2 is rapidly recruited to DNA damage sites in a PARP1-dependent manner; BRN2 facilitates Ku80 recruitment and promotes non-homologous end joining (NHEJ) at the expense of homologous recombination; BRN2 also suppresses an apoptosis-associated gene expression program, protecting against UVB-, chemotherapy-, and vemurafenib-induced apoptosis.\",\n      \"method\": \"Co-immunoprecipitation, live-cell imaging of DNA damage recruitment, NHEJ/HR repair assays, gene expression analysis, apoptosis assays\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP with PARP1/Ku proteins, PARP1-dependency demonstrated, multiple functional DNA repair and apoptosis assays, mechanistically distinct from transcriptional role\",\n      \"pmids\": [\"30804224\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Loss of CDKN2A leads to increased BRN2 expression via E2F1; E2F1 directly regulates BRN2 transcription; BRN2 inhibition rescues metastatic dissemination caused by CDKN2A loss in human melanoma lines in mice, placing BRN2 downstream of CDKN2A/p16-E2F1 in melanoma invasion initiation.\",\n      \"method\": \"CRISPR-Cas9 engineering of primary human melanocytes, xenograft models, E2F1 promoter binding assays\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — CRISPR-engineered primary human cells, in vivo rescue experiment, direct E2F1 regulation demonstrated, multiple orthogonal methods\",\n      \"pmids\": [\"29990501\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"BRN2 activates NOTCH pathway signaling in melanoma cells, while MITF represses it; siRNA-mediated depletion of BRN2 decreased NOTCH pathway member expression, and depletion of MITF increased it; loss of both BRN2 and MITF decreased melanosphere-forming capability, cell adhesion, and invasion.\",\n      \"method\": \"siRNA knockdown, gene expression analysis, melanosphere formation assay, invasion assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA-based loss-of-function with multiple phenotypic readouts and pathway analysis, single lab\",\n      \"pmids\": [\"21358674\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"BRN2 is required for expression of ASCL1, ND1, and neuroendocrine markers (NCAM1, SYP, CHGA) in small cell lung cancer cells; BRN2 knockdown in SCLC cells causes significant growth retardation with decreased S-to-G2 phase population; forced BRN2 expression in non-SCLC cells induces expression of these neuroendocrine markers, placing BRN2 as a higher-level regulator than ASCL1 and ND1.\",\n      \"method\": \"siRNA knockdown, ectopic expression, cell cycle analysis, growth assays\",\n      \"journal\": \"Pathology international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — bidirectional (knockdown and overexpression) functional experiments with defined phenotypic readouts, single lab\",\n      \"pmids\": [\"23530560\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"BRN2 directly activates TTF1 expression in SCLC cells by binding to the TTF1 isoform 2 promoter; BRN2 binding to the TTF1 promoter was confirmed by chromatin immunoprecipitation; BRN2 knockdown significantly reduced TTF1 expression.\",\n      \"method\": \"Promoter reporter assays, ChIP, siRNA knockdown\",\n      \"journal\": \"Laboratory investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct promoter binding confirmed by ChIP plus functional knockdown, single lab\",\n      \"pmids\": [\"23358112\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Brn-2 directly interacts with Jab1 (Jun-activation-domain-binding protein 1); interaction was identified by yeast two-hybrid and confirmed by surface plasmon resonance biosensor.\",\n      \"method\": \"Yeast two-hybrid screen, surface plasmon resonance biosensor\",\n      \"journal\": \"Neuroscience letters\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — protein interaction confirmed by two methods but functional consequence not established, single lab\",\n      \"pmids\": [\"15911144\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Brn-2 activates the neuronal promoter of the aromatic L-amino acid decarboxylase (AADC) gene; NF-Y binding is required for Brn-2-mediated transactivation; Brn-2 directly interacts with NF-Y via its POU domain (GST-pulldown), and NF-Y and Brn-2 bind cooperatively to the AADC neuronal promoter.\",\n      \"method\": \"Reporter gene assays, dominant-negative NF-Y, GST-pulldown, EMSA\",\n      \"journal\": \"Brain research. Molecular brain research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro binding reconstitution (GST-pulldown and EMSA) combined with functional reporter assays, single lab\",\n      \"pmids\": [\"11311976\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Brn-2 POU domain dimerizes cooperatively on a palindromic MORE+2-type element (TB motif) in the AADC neuronal promoter; site-directed mutagenesis of the POU-specific domain hydrophobic pocket and C-terminal POU homeodomain abolished dimerization on TB; both TB and ONF sites contribute to Brn-2-mediated promoter activation.\",\n      \"method\": \"EMSA with POU domain mutants, site-directed mutagenesis, reporter assays in COS-7 cells\",\n      \"journal\": \"Brain research. Molecular brain research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis defining dimerization interface combined with functional reporter assays, single lab\",\n      \"pmids\": [\"14741405\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"BRN2 drives melanoma cell migration and invasion through induction of NFIB; NFIB in turn upregulates EZH2, which epigenetically suppresses MITF expression; this BRN2-NFIB-EZH2-MITF axis promotes an invasive, less proliferative melanoma phenotype.\",\n      \"method\": \"Overexpression and siRNA knockdown experiments, migration/invasion assays, gene expression analysis\",\n      \"journal\": \"EBioMedicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis established through sequential knockdown/overexpression with defined phenotypic readouts, single lab\",\n      \"pmids\": [\"28119061\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"POU-III transcription factors Pou3f2 (Brn2) and Pou3f3 (Brn1) are expressed in ventricular zone progenitors and function to promote upper-layer cortical neuron fate; using an Engrailed dominant-negative repressor, sustained neurogenesis after the deep-to-upper-layer transition requires Pou3f activity; single-gene overexpression of any Pou3f in early neural progenitors is sufficient to specify precocious Satb2+ upper-layer neuron birth. Pou3fs suppress Notch effector Hes5 and promote Tbr2 and Tbr1 expression.\",\n      \"method\": \"Dominant-negative repressor, single-gene overexpression, marker analysis, in utero electroporation\",\n      \"journal\": \"Cerebral cortex\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — dominant-negative and overexpression with defined lineage markers, pathway placement via Notch/Tbr2, single lab\",\n      \"pmids\": [\"22892427\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Brn2 is essential for the neuronal differentiation program in retinoic acid-treated embryonic stem cells; integrated RNA-seq (after Brn2 silencing) and ChIP-seq identified Zic1 as a direct Brn2 target gene; shRNA silencing of Zic1 blocked neural precursor specification, defining a hierarchical Brn2-Zic1 axis specifying neuronal fate.\",\n      \"method\": \"shRNA knockdown, RNA-seq, ChIP-seq, differentiation assays\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide ChIP-seq integrated with RNA-seq, epistasis confirmed via downstream target knockdown, multiple orthogonal methods\",\n      \"pmids\": [\"25991548\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"A prenatal β-catenin/Brn2/Tbr2 transcriptional cascade governs basal neural progenitor cell expansion; in Dvl1/Dvl3 mutant mice with social and repetitive behavioral abnormalities, this cascade is deregulated; pharmacological Wnt activation rescues the transcriptional cascade and prevents adult behavioral deficits.\",\n      \"method\": \"Genetic mouse model (Dvl mutants), pharmacological Wnt activation, transcriptional cascade analysis\",\n      \"journal\": \"Molecular psychiatry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cascade validated by rescue experiment in defined genetic model, single lab\",\n      \"pmids\": [\"26830142\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"POU3F2 lies downstream of SIM1 and controls oxytocin expression in the hypothalamic neuroendocrine preoptic area, as demonstrated using morpholino and mutant zebrafish models.\",\n      \"method\": \"Morpholino knockdown and mutant zebrafish models, oxytocin expression analysis\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with defined molecular phenotype (oxytocin expression) in two model systems, epistasis to SIM1 established\",\n      \"pmids\": [\"26833329\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"POU3F2 directly regulates NTF3 promoter activity; POU3F2 binds to the NTF3 promoter as demonstrated by ChIP-seq and mutation/deletion of the POU3F2 binding site in the NTF3 promoter decreased luciferase reporter activity; POU3F2 knockdown downregulates NTF3 expression; exogenous NTF3 rescues neuronal differentiation in POU3F2-knockdown cells.\",\n      \"method\": \"ChIP-seq, promoter luciferase reporter assays with binding site mutation, siRNA knockdown, rescue experiments\",\n      \"journal\": \"Molecular neurobiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct binding confirmed by ChIP-seq plus mutagenesis of binding site and functional rescue, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"29549646\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"POU3F2 regulates TRIM8 expression by binding to a SNP-containing promoter element (rs5011218); luciferase reporter and EMSA showed that POU3F2 binds this element and that the SCZ-associated SNP affects binding efficiency; POU3F2 or TRIM8 knockdown in neural progenitor cells promotes NPC proliferation, inhibits neuronal differentiation, and impairs excitatory synaptic transmission.\",\n      \"method\": \"Luciferase reporter assays, EMSA, RNA-seq after knockdown, functional NPC assays, electrophysiology\",\n      \"journal\": \"Molecular psychiatry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct promoter binding with EMSA plus functional cellular assays, single lab, multiple methods\",\n      \"pmids\": [\"32929213\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Brn2 associates with condensed chromatin throughout cell division in neural stem cells (live-cell imaging); ChIP-seq shows Brn2 mitotic chromosome binding is not sequence-specific (relies mostly on electrostatic forces); competing with Brn2 binding during mitotic exit using a mitotic-specific dominant-negative reduces transcription of its target gene Nestin, demonstrating Brn2's role in early transcriptional reactivation during mitosis-to-G1 transition.\",\n      \"method\": \"Live-cell imaging, ChIP-seq, single-molecule RNA-FISH, mitotic dominant-negative approach\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — live-cell imaging combined with genome-wide ChIP-seq, smRNA-FISH, and functional dominant-negative, multiple orthogonal methods in single study\",\n      \"pmids\": [\"34168041\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Mutant huntingtin N-terminal fragment (from R6/2 HD mice) sequesters Brn-2, reducing its DNA binding; mutant huntingtin also reduces Brn-2 transcription; both mechanisms reduce Brn-2 function, leading to reduced hypothalamic neuropeptide expression. Brn-1, a related protein, is not sequestered.\",\n      \"method\": \"Comprehensive analysis of transcription factor DNA binding, protein interaction studies, R6/2 model mice\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — DNA binding and protein interaction assays in vivo in disease model, with negative control (Brn-1 not sequestered), single lab\",\n      \"pmids\": [\"20185558\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"BRN2 directly binds PARP1 and Ku70/Ku80 and is rapidly recruited to DNA damage sites in a PARP1-dependent manner; BRN2 facilitates Ku80 recruitment and promotes non-homologous end-joining (NHEJ) at the expense of homologous recombination; this is associated with high somatic mutation burden in melanoma.\",\n      \"method\": \"Co-immunoprecipitation, live-cell imaging, NHEJ/HR repair pathway assays\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, PARP1-dependency experiment, multiple repair pathway assays, mechanistically novel finding with multiple methods\",\n      \"pmids\": [\"30804224\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"BRN2 expression increases anoikis resistance in melanoma cells; induction of BRN2 increases c-MET protein levels and STAT3 phosphorylation; treatment with c-MET inhibitors decreases viability of BRN2-expressing cells under non-adherent conditions.\",\n      \"method\": \"Doxycycline-inducible BRN2 expression, genome-wide profiling, non-adherent viability assays, c-MET inhibitor treatment\",\n      \"journal\": \"Oncogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — inducible expression system with genome-wide profiling and pharmacological validation, single lab\",\n      \"pmids\": [\"32632141\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BRN2 directly induces PTEN expression and represses PI3K signaling; BRN2 haplo-insufficiency in a BrafV600E/PtenF/+ context promotes melanoma initiation and metastasis; MITF (a BRN2 target) represses PTEN transcription, suggesting a tumor suppressive role for BRN2 via PTEN induction.\",\n      \"method\": \"Conditional knockout mouse models, promoter binding assays, PI3K signaling analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo conditional knockout model with mechanistic promoter analysis, single lab\",\n      \"pmids\": [\"34140478\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"BRAF regulates MITF expression through a BRN2/PAX3 rheostat: PAX3 activates MITF transcription while BRN2 represses it; the balance between BRN2 and PAX3 determines MITF expression plasticity, providing robustness during MAPK inhibitor treatment.\",\n      \"method\": \"Reporter assays, knockdown/overexpression, quantification of transcription factor levels\",\n      \"journal\": \"Pigment cell & melanoma research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic reporter and epistasis assays identifying BRN2/PAX3 competition, single lab\",\n      \"pmids\": [\"30277012\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Cdk5 phosphorylates Tet3 at S1310 and S1379 in its catalytic domain; phosphorylated Tet3 generates higher 5hmC levels at the BRN2 promoter (compared to phospho-mutant Tet3), correlating with higher BRN2 expression and more efficient neuronal differentiation of ESCs; differential H2A.Z occupancy at BRN2 promoter also participates in this regulation.\",\n      \"method\": \"In vitro dioxygenase assay with phospho-mutant Tet3, 5hmC mapping at BRN2 promoter, ESC differentiation assays, Tet triple-KO rescue experiments\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — phospho-mutant analysis with promoter 5hmC measurement and functional differentiation readout, single lab with multiple methods\",\n      \"pmids\": [\"31807777\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"POU3F2 regulates a coexpression network module in brain; knockdown and overexpression experiments in neural cells validate POU3F2 as a regulator of hsa-miR-320e and target mRNAs in this module; POU3F2 knockdown or overexpression in SH-SY5Y cells and human neural progenitor cells modulates gene expression in schizophrenia/bipolar-associated gene networks.\",\n      \"method\": \"siRNA knockdown and overexpression in neural cell lines and human neural progenitor cells, RNA-seq\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — bidirectional expression manipulation in relevant cell types with transcriptomic validation, replicated in PsychENCODE datasets\",\n      \"pmids\": [\"30545964\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BRN2 in cynomolgus monkey biallelic knockout (lethal before midgestation) decreases radial glia cell expansion, induces precocious differentiation, and alters neurogenesis trajectory in the telencephalon; BRN2 directly regulates SOX2 and STAT3 and maintains HOPX expression; BRN2 controls specification and differentiation of ganglionic eminences, revealing primate-specific mechanistic functions.\",\n      \"method\": \"Biallelic knockout in cynomolgus monkeys (CRISPR), single-cell transcriptome, histology, target gene expression analysis\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo biallelic knockout in non-human primate combined with single-cell transcriptomics and target gene validation, novel mechanistic finding\",\n      \"pmids\": [\"35245119\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BRN1 and BRN2 have an evolutionarily conserved function in neocortical progenitors to control proliferative capacity and the switch from direct to indirect neurogenesis; BRN1/2 act in concert with NOTCH and primary microcephaly genes; this is validated in mice, ferrets, and transcriptomic data from genetically modified macaques.\",\n      \"method\": \"Conditional knockout in mice and ferrets, transcriptomics in genetically modified macaques, functional epistasis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multi-species genetic and functional validation with cross-species replication and defined cellular phenotypes\",\n      \"pmids\": [\"39271675\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"POU3F2 mutation in human neural progenitor cells reduces canonical Wnt signalling and decreases proliferation, causing premature radial glia specification; SOX13 and ADNP are direct transcriptional targets of POU3F2 that mediate its effects on Wnt signaling; loss-of-function mutations in POU3F2 are found in individuals with autism spectrum disorder.\",\n      \"method\": \"CRISPR-mediated POU3F2 disruption in human NPCs, RNA-seq, ChIP-seq, Wnt pathway reporter assays\",\n      \"journal\": \"Brain\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR loss-of-function in human NPCs with target gene validation via multiple omics approaches, single lab\",\n      \"pmids\": [\"40498903\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"POU3F2 promotes radioresistance in triple-negative breast cancer by interacting with ARNT2 and enhancing Akt pathway activation; Co-IP demonstrated POU3F2-ARNT2 interaction; POU3F2 knockdown decreased radioresistance and reduced proliferation and invasion.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, clonogenic survival assays, xenograft model\",\n      \"journal\": \"Breast cancer research and treatment\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — Co-IP plus functional knockdown with multiple assays including in vivo, single lab\",\n      \"pmids\": [\"36797433\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"RFX4 directly interacts with the promoters of POU3F2 and NEUROD1, acting as an upstream regulator; ectopic expression of RFX4 drives human embryonic stem cells toward a neuronal fate; CRISPR-Cas9 knockout of RFX4 reduces POU3F2 expression and impairs neuronal differentiation.\",\n      \"method\": \"Multi-omics (ATAC-seq, ChIP-seq, Hi-C, RNA-seq), RFX4 knock-in and CRISPR-Cas9 knockout, neuronal differentiation assays\",\n      \"journal\": \"Cellular and molecular life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct promoter binding confirmed by ChIP-seq and multi-omics, bidirectional functional validation, single lab\",\n      \"pmids\": [\"38386071\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Integrin α3β1 promotes BRN2 expression in triple-negative breast cancer cells via Akt signaling; RNAi suppression of α3β1 reduces Brn-2 mRNA, protein, and BRN2 promoter activity; Akt inhibitor reduces both Brn-2 expression and invasion; exogenous Brn-2 partially restores invasion in α3β1-suppressed cells.\",\n      \"method\": \"RNAi knockdown, promoter reporter assays, pharmacological Akt inhibition, invasion assays in vitro and in vivo\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis through knockdown, pharmacological inhibition, and rescue experiments, multiple functional assays, single lab\",\n      \"pmids\": [\"33513758\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Deletion of the three homopolymeric amino acid repeats (polyG, polyQ, polyP) from the Pou3f2 transactivation domain (Pou3f2Δ/Δ mice) causes cognitive impairment and reduced adult hippocampal neurogenesis, with fewer newborn neurons in the dentate gyrus, demonstrating a functional role for these mammalian-specific repeats in cognitive function and neurogenesis.\",\n      \"method\": \"Knock-in mouse model, behavioral testing (object recognition/location), immunohistochemistry for doublecortin and BrdU/NeuN co-labeling\",\n      \"journal\": \"Genes, brain, and behavior\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — knock-in mouse model with defined domain deletion, multiple behavioral and cellular readouts, single lab\",\n      \"pmids\": [\"28782255\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Replacement of mammalian Pou3f2 with the Xenopus ortholog lacking homopolymeric amino acid repeats (nonmammalized mice) causes deficits in maternal pup retrieval behavior and decreases in dopamine and serotonin synthesis rate-limiting enzymes; knock-in mice lacking the mammalian-specific polyAA repeats show similar results, demonstrating that these mammalian-specific sequences are required for normal monoamine levels and maternal behavior.\",\n      \"method\": \"Knock-in mice with Xenopus ortholog replacement, knock-in mice with polyAA deletions, behavioral testing, immunohistochemical quantification of monoamine synthesis enzymes\",\n      \"journal\": \"Genome biology and evolution\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two complementary knock-in models with defined molecular and behavioral phenotypes, single lab\",\n      \"pmids\": [\"24709564\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Brn-2 is required as an intermediary for retinoic acid-induced CRF gene transcription in human neuroblastoma BE(2)-M17 cells; antisense Brn-2 aborts RA-mediated CRF induction, but Brn-2 overexpression alone is not sufficient for CRF expression without RA.\",\n      \"method\": \"Antisense RNA inhibition, ectopic overexpression, reporter gene assays\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, antisense inhibition with limited mechanistic follow-up, negative overexpression result also reported\",\n      \"pmids\": [\"10446900\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"BRN2 knockdown does not alter nestin expression in melanoma cells (negative result); SOX9 and SOX10, but not BRN2, are required for nestin expression in melanoma cells, as SOX9/SOX10 knockdown markedly decreased nestin levels.\",\n      \"method\": \"siRNA knockdown, Western blot and mRNA analysis\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean siRNA knockdown with clear negative result for BRN2 and positive result for SOX9/SOX10, single lab\",\n      \"pmids\": [\"18923447\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Adenoviral overexpression of Brn-2 in the rat paraventricular nucleus had no effect on vasopressin hnRNA levels, and did not upregulate CRF mRNA in vivo, despite Brn-2 transactivating the proximal CRF promoter in vitro; this indicates Brn-2 is not rate-limiting for VP or CRF expression in adult hypothalamus.\",\n      \"method\": \"Adenoviral-mediated in vivo overexpression in rat PVN, hnRNA and mRNA analysis\",\n      \"journal\": \"Molecular and cellular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct in vivo overexpression experiment with clear negative result in adult tissue, single lab\",\n      \"pmids\": [\"12644309\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"POU3F2/BRN2 is a class III POU domain transcription factor that functions as a sequence-specific transcriptional activator and repressor (of MITF, CDH13, PTEN) and a direct regulator of neural lineage specification, hypothalamic neurosecretory neuron differentiation, Schwann cell myelination (via direct Krox20 enhancer activation), and cortical progenitor behavior; in melanoma it sits downstream of BRAF/MAPK, Wnt/β-catenin, PI3K-Pax3, and CDKN2A-E2F1 signaling to drive invasion and phenotype switching, and also associates non-transcriptionally with PARP1 and Ku70/Ku80 at DNA damage sites to promote error-prone NHEJ repair and suppress apoptosis.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"POU3F2 (BRN2) is a class III POU-domain transcription factor that acts as a master regulator of neural lineage specification and neuronal differentiation, and is co-opted in cancer as a driver of phenotype switching and invasion [#1, #24, #15]. In the nervous system it is required at a penultimate step of hypothalamic neurosecretory neuron differentiation, enabling activation of neuropeptide genes including vasopressin and oxytocin [#0], and it sits downstream of SIM1 to control oxytocin expression [#26]. In cortical and stem-cell neurogenesis it governs progenitor proliferative capacity and the switch from direct to indirect neurogenesis, suppressing the Notch effector Hes5 while promoting Tbr2/Tbr1 and acting through direct targets including Zic1, NTF3, SOX2, SOX13 and ADNP [#23, #24, #27, #37, #39, #38]. In Schwann cells it functions redundantly with Oct-6 to drive the promyelinating-to-myelinating transition by directly activating a Krox20 enhancer in synergy with Sox10 [#2, #3]. Mechanistically, BRN2 binds DNA through its POU domain, can homodimerize on palindromic MORE-type elements, and its activity is tuned by phosphorylation within the POU domain (T361/S362), which switches its transcriptional output between proliferative and migratory programs [#21, #11]. In melanoma, BRN2 integrates BRAF/MAPK, Wnt/\\u03b2-catenin, PI3K-Pax3, and CDKN2A-E2F1 inputs and occupies thousands of genomic loci, where it directly represses MITF and CDH13 and activates an invasive program partly through an NFIB-EZH2 axis and KIT-ligand signaling [#4, #5, #10, #15, #6, #9, #22]. The BRN2/PAX3 balance forms a rheostat setting MITF plasticity during MAPK inhibition, and BRN2 also induces PTEN to restrain PI3K signaling, giving it a context-dependent tumor-suppressive role [#34, #33]. Beyond transcription, BRN2 performs a non-transcriptional function at sites of DNA damage, binding PARP1 and Ku70/Ku80, promoting Ku80 recruitment and error-prone non-homologous end-joining while suppressing apoptosis [#31, #14]. BRN2 is also required for neuroendocrine differentiation programs in prostate and small-cell lung cancers downstream of androgen receptor suppression [#13, #17]. Loss-of-function POU3F2 mutations are found in individuals with autism spectrum disorder [#39].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Established BRN2 as a genetically required factor for terminal differentiation of hypothalamic neurosecretory neurons, defining its developmental role in vivo.\",\n      \"evidence\": \"Germline gene knockout in mice with histology and neuropeptide gene expression analysis\",\n      \"pmids\": [\"8543156\", \"8543155\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets at the neuropeptide loci not defined\", \"Did not establish whether the requirement is cell-autonomous\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Showed BRN2 is required to establish neural cell lineages rather than merely refine them, since its loss diverts embryonal carcinoma cells to non-neural fates.\",\n      \"evidence\": \"Antisense RNA inhibition in P19 cells with lineage marker analysis\",\n      \"pmids\": [\"8274283\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No direct target genes identified\", \"Antisense specificity not orthogonally confirmed\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Defined BRN2 as functionally redundant with Oct-6 in driving Schwann cell myelination, resolving how POU-III factors cooperate in peripheral glia.\",\n      \"evidence\": \"Transgenic overexpression rescue in Oct-6 knockout and compound knockout in mice\",\n      \"pmids\": [\"12782656\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the direct enhancer targets driving the transition (addressed later)\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Placed BRN2 directly upstream of Krox20 in the myelination hierarchy by identifying a bound enhancer element and Sox10 synergy.\",\n      \"evidence\": \"Reporter assays, transgenic enhancer analysis and TF binding studies\",\n      \"pmids\": [\"16311519\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of BRN2/Oct-6/Sox10 occupancy not resolved\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Defined BRN2's biochemical interaction repertoire, showing homodimerization via homeodomain/linker and low-affinity contacts with general and melanocyte transcription factors.\",\n      \"evidence\": \"GAL4-VP16 two-hybrid, GST-pulldown and EMSA with melanoma nuclear extracts\",\n      \"pmids\": [\"11029584\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of TBP/p300/Sox10/Pax3 contacts not established\", \"In vitro affinities not validated in cells\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Identified BRN2 as a downstream effector of both BRAF/MAPK and Wnt/\\u03b2-catenin signaling driving melanoma proliferation, integrating two oncogenic inputs at a single transcription factor.\",\n      \"evidence\": \"Promoter reporter assays, siRNA knockdown and transgenic mice with proliferation assays\",\n      \"pmids\": [\"15024080\", \"15024079\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream proliferative targets of BRN2 not enumerated in these studies\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Revealed BRN2 as a regulator of melanoma heterogeneity by directly repressing MITF, with the two factors marking mutually exclusive tumor subpopulations.\",\n      \"evidence\": \"Promoter reporter assays, siRNA knockdown and biopsy immunohistochemistry\",\n      \"pmids\": [\"18829533\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of switching between BRN2-high and MITF-high states not defined\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Mapped BRN2's genome-wide occupancy in melanoma (~2108 loci), establishing it as a broad regulator including direct control of MITF and KIT-ligand signaling.\",\n      \"evidence\": \"ChIP-chip occupancy profiling with luciferase reporter validation\",\n      \"pmids\": [\"20337985\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence validated only for Kitl\", \"ChIP-chip lower resolution than later ChIP-seq\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Showed BRN2 transcriptional output is switched by POU-domain phosphorylation at T361/S362, explaining how one factor toggles between proliferation and migration programs.\",\n      \"evidence\": \"Point mutagenesis with transgenic mouse and in vitro phenotypic assays\",\n      \"pmids\": [\"22290434\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinase responsible for T361/S362 phosphorylation not identified\", \"Structural basis of the phospho-switch unresolved\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Connected upstream PI3K-Pax3 signaling and downstream CDH13 repression to BRN2, extending its melanoma invasion circuitry.\",\n      \"evidence\": \"Promoter binding/EMSA, PI3K inhibition, siRNA knockdown and invasion assays\",\n      \"pmids\": [\"22988297\", \"23069940\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cross-talk between PI3K-Pax3 and MAPK inputs not integrated\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Established BRN2 as a high-level driver of neuroendocrine differentiation in small-cell lung cancer, upstream of ASCL1/ND1 and directly activating TTF1.\",\n      \"evidence\": \"siRNA knockdown, ectopic expression, ChIP and cell-cycle assays in SCLC cells\",\n      \"pmids\": [\"23530560\", \"23358112\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect regulation of ASCL1/ND1 not fully separated\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Used integrated ChIP-seq/RNA-seq to define a direct BRN2-Zic1 axis required for neuronal fate specification in differentiating ESCs.\",\n      \"evidence\": \"shRNA knockdown with RNA-seq, ChIP-seq and differentiation assays\",\n      \"pmids\": [\"25991548\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Zic1 may be one of several effectors; full direct target set not parsed\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Embedded BRN2 in a \\u03b2-catenin/Brn2/Tbr2 cascade controlling basal progenitor expansion and linked its deregulation to behavioral abnormalities rescuable by Wnt activation.\",\n      \"evidence\": \"Dvl mutant mouse model with pharmacological Wnt activation and SIM1-epistasis zebrafish models\",\n      \"pmids\": [\"26830142\", \"26833329\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect position of BRN2 within the \\u03b2-catenin/Tbr2 cascade not fully resolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified the BRN2-NFIB-EZH2-MITF axis as a mechanism by which BRN2 epigenetically suppresses MITF to promote invasive, low-proliferative melanoma states.\",\n      \"evidence\": \"Overexpression/siRNA knockdown with migration/invasion and expression assays\",\n      \"pmids\": [\"28119061\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect induction of NFIB not distinguished\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Placed BRN2 downstream of androgen-receptor suppression and CDKN2A-E2F1, establishing it as a driver of neuroendocrine prostate differentiation and melanoma metastasis initiation.\",\n      \"evidence\": \"ChIP of AR/E2F1 at BRN2 promoter, CRISPR-engineered primary cells, xenograft and in vivo rescue\",\n      \"pmids\": [\"27784708\", \"29990501\", \"30277012\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How BRN2 selects invasion vs differentiation programs across tissues not defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Uncovered a non-transcriptional role for BRN2 at DNA damage sites, where it binds PARP1 and Ku70/80 to promote error-prone NHEJ and suppress apoptosis.\",\n      \"evidence\": \"Reciprocal Co-IP, live-cell damage recruitment, NHEJ/HR repair assays and apoptosis assays\",\n      \"pmids\": [\"30804224\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether DNA-binding domain or POU domain mediates the repair function unclear\", \"Link between transcriptional and repair functions not integrated\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Revealed BRN2's behavior on mitotic chromatin, binding condensed chromosomes non-sequence-specifically to enable early transcriptional reactivation of targets like Nestin during mitotic exit.\",\n      \"evidence\": \"Live-cell imaging, ChIP-seq, single-molecule RNA-FISH and mitotic dominant-negative\",\n      \"pmids\": [\"34168041\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How non-specific mitotic binding transitions to specific G1 occupancy unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstrated a context-dependent tumor-suppressive function whereby BRN2 directly induces PTEN to restrain PI3K signaling, opposing its pro-invasive activity.\",\n      \"evidence\": \"Conditional knockout mouse models with promoter binding and PI3K signaling analysis\",\n      \"pmids\": [\"34140478\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Determinants of pro- versus anti-tumor BRN2 output not defined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Extended BRN2's neurogenic function to primate and cross-species cortical development, controlling radial glia expansion and the direct-to-indirect neurogenesis switch via SOX2/STAT3/HOPX and NOTCH interplay.\",\n      \"evidence\": \"Biallelic CRISPR knockout in cynomolgus monkeys and conditional knockouts in mice/ferrets with single-cell transcriptomics\",\n      \"pmids\": [\"35245119\", \"39271675\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Primate-specific regulatory mechanisms not fully dissected at the cis level\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Linked POU3F2 loss-of-function to autism via reduced Wnt signaling and premature radial glia specification, identifying SOX13 and ADNP as direct mediating targets.\",\n      \"evidence\": \"CRISPR disruption in human NPCs with RNA-seq, ChIP-seq and Wnt reporter assays\",\n      \"pmids\": [\"40498903\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Genotype-phenotype correlation in patients not established\", \"Single-lab human NPC model\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How BRN2 integrates its sequence-specific transcriptional, mitotic-bookmarking, and DNA-repair activities into a unified control of cell fate and survival remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model linking POU-domain DNA binding to PARP1/Ku association\", \"Kinases and signals that select among BRN2's divergent outputs are unmapped\", \"Whether DNA-repair function operates outside melanoma is untested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 3, 6, 11, 24, 27]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [9, 12, 21, 29]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [7, 11, 29]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [29]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [3, 6, 24, 27]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [0, 2, 23, 37, 38]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [4, 13, 15, 33, 39]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [14, 31]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [5, 10, 16]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"PARP1\", \"XRCC6\", \"XRCC5\", \"PAX3\", \"SOX10\", \"NFYB\", \"ARNT2\", \"PQBP1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":10,"faith_total":10,"faith_pct":100.0}}